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CHAPTER I 
 
PHARMACOLOGICAL AND ELECTROPHYSIOLOGICAL 
 PROPERTIES OF METABOTROPIC GLUTAMATE RECEPTORS 
 
Metabotropic Glutamate Receptors 
 
Molecular identity, structure, activation mechanism and signaling.  
Glutamate is the major excitatory neurotransmitter in the mammalian central 
nervous system (CNS) and is responsible for the majority of fast excitatory synaptic 
responses at CNS synapses (Dingledine et al., 1999).  Fast synaptic responses at 
glutamatergic synapses are mediated by activation of glutamate gated cation channels 
termed ionotropic glutamate receptors (iGluRs).  In addition, glutamate activates 
metabotropic glutamate receptors (mGluRs), which are coupled to GTP-bindinG-proteins 
(G-protein) (Conn and Pin, 1997).  Unlike iGluRs, mGluRs modulate synaptic 
transmission and cell excitability through second messenger systems. Because of the 
ubiquitous distribution of glutamatergic synapses, mGluRs participate in regulating a 
wide variety of CNS functions (Conn and Pin, 1997; Anwyl, 1999; Coutinho and Knopfel, 
2002). 
mGluRs belong to family C of G-protein-coupled receptors (GPCRs). Eight 
family members of mGluRs have been cloned from rat and human genomes to date. 
Based on their sequence homology, pharmacological selectivity and primary G-protein 
coupling, mGluRs are further divided into three groups (Figure 1-1). Group 1 mGluRs 
include mGluR1 and mGluR5, both of which are coupled to Gq/11 to activate 
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phospholipase C (PLC). Group 2 mGluRs (mGluR2 and mGluR3) and Group 3 mGluRs 
(mGluR4, mGluR6, mGluR7 and mGluR8) are coupled to Gi/o to inhibit adenylyl cyclase 
activity, which results in a decrease of cyclic AMP (cAMP) accumulation.  
 
 
 
 
Figure 1-1: Classification of mGluRs. Eight mGluRs are divided into three groups based 
on their sequence homolog and primary G-protein coupling. (Figure modified from Conn 
2003) 
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All eight mGluR subtypes contain three major domains, a large extracellular N-
terminal domain, a heptahelical domain containing seven transmembrane regions linked 
by short loops, and an intracellular C-terminal domain (Figure 1-2). Unlike family A and 
B GPCRs, glutamate binds to the N-terminal extracellular domains of mGluRs. This 
orthosteric binding site is highly conserved through out all the mGluR subtypes. It has 
been proposed that the mGluR extracellular domain has a sequence similarity with 
bacterial periplasmic bindinG-proteins (PBP) (O'Hara et al. 1993). This homology has 
been used to construct a model based on the structure of PBPs, which predicted the 
mGluRs N-terminal domains to be made up of two globular domains with a hinge region. 
This “Venus FlyTrap” structure was confirmed by a crystallography study of the mGluR1 
extracellular domain at 2.2Å resolution later (Kunishima et al., 2000). In addition, this 
model predicted glutamate binding to the N-terminal domain, which was supported by 
mutagenesis studies ((Takahashi et al., 1993; Tones et al., 1995 and Parmentier et al., 
1998; Pin et al., 2003). Glutamate induced closure of the “Venus FlyTrap” domain leads 
to the activation of the receptor (Kunishima et al., 2000; Tsuchiya et al., 2002; Pin et al., 
2004). mGluRs possess the typical seven transmembrane (TM) domains linked with 
loops as other families of GPCRs (Conn and Pin 1997; Bhave et al., 2003).  It has been 
proposed that the TM domains interact with the N-terminal domain allosterically to 
transduce the extracellular stimulus into an intracellular response. The intercellular loops 
and C-terminal tail are both crucial for the selective coupling to different G-proteins (Pin 
et al., 1994; Gomeza et al., 1996 and De Blasi et al., 2001). The major splice isoforms of 
mGluRs’ are only different in the intracellular C-terminal tails. For instance, at least 5 
isoforms of mGluR1 have been shown to exist, named as mGluR1a/1b/1c/1d/1e 
 3
individually (Pin et al., 1992; Tanabe et al., 1992; Laurie et al., 1996; Mary et al., 1997). 
All mGluR1 sequences are identical up to the forty-sixth residue of the intracellular tail, 
followed by 313, 20, 11, and 26 residues for mGluR1a, mGluR1b, mGluR1c, and 
mGluR1d respectively (Mary et al., 1998). The different variants are all coupled to Gq/11 
but show different activation kinetics and constitutive activities (Mary et al., 1998). This 
indicates that the intracellular tails of mGluRs may control their activation kinetics.  
mGluRs can couple to multiple signaling pathways besides the primary G-
proteins. mGluRs are classified as GPCRs because they activate intracellular signaling 
pathways that begin with G-proteins. However, evidence suggests that mGluRs also 
trigger signaling pathways independent of G-protein activation. For instance, in 
hippocampus, mGluR1 activation simultaneously triggers both G-protein-dependent and -
independent signaling induced distinct currents (Heuss et al., 1999; Gee et al., 2004). 
Consistent with this, inward currents mediated by mGluRs in hippocampus still persisted 
in G-protein knockout mice (Krause et al., 2004). Additionally, in CA3 pyramidal 
neurons, N-methyl-D-aspartate (NMDA) receptor current is potentiated by mGluR5 by a 
G-protein-dependent manner, whereas NMDAR current potentiation by mGluR1 is 
independent of G-protein activation (Benquet et al., 2002). It is possible that different 
signaling pathways are responsible for different responses mediated by a single subtype 
of mGluR. Interestingly, increasing evidence suggests that different orthosteric agonists 
can differentially activate distinct signaling pathways of a single GPCR, a phenomenon 
termed as agonist receptor trafficking (Berg et al., 1998; Brink et al., 2000; Gazi et al., 
2003). Thus, compounds with high selectivity to one certain signaling pathway of one 
receptor may have better therapeutic properties compared with the compounds only 
 4
selective to the receptor. This has become important for development of novel 
pharmacological reagents to regulate distinct signaling pathways differentially according 
to certain therapeutic purposes.  
 
 
Glutamate Binding 
Domain 
 
 
 
Cysteine Rich  
Domain 
 
 
7TM Domain 
 
G-protein Binding  
Domain 
 
Intracellular Tail 
 
Figure 1-2: Schematic structure of an mGluR. The cysteine residues in the cysteins rich 
domain are indicated with black circles. The segment within the second intracellular loop 
that is important for G-protein coupling specificity is indicated in black. (Figure modified 
from Conn and Pin 1997) 
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Physiological effects and diseases relevance.  
mGluRs exist predominantly in many regions of the mammalian nervous system, 
where they modulate neuronal excitability and synaptic transmission through activation 
of second messenger systems. Activation of mGluRs results in a diverse range of 
electrophysiological effects, such as inhibition of potassium and calcium currents, 
activation of potassium, calcium and non-specific cation currents, induction of slow 
excitatory postsynaptic potentials, inhibition of presynaptic neurotransmitter release, and 
potentiation of synaptic amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptor  and N-methyl-D-aspartate (NMDA) receptor currents (Anwyl 1999). mGluRs 
are potential drug targets for many neurological and psychiatric disorders, including 
Parkinson's disease (Marino and Conn, 2002b), epilepsy (Doherty and Dingledine, 2002), 
Alzheimer's disease (Wisniewski and Carr, 2002), pain (Varney and Gereau, 2002), 
schizophrenia (Marino and Conn, 2002a), depression (Palucha and Pilc, 2002), and 
anxiety disorders (Chojnacka-Wojcik et al., 2001; Pilc, 2003). Thus, it has become 
critical to develop subtype selective pharmacological reagents to study the potential 
involvement of mGluRs in different human disorders that may be relevant to the 
development of new therapeutic agents.  
 
Pharmacology of mGluRs.  
Much effort has been focused on the development of selective compounds to 
either activate (agonist) or inhibit (antagonist) mGluR responses. The first generation of 
compounds includes primarily analogs or derivatives of glutamate, the endogenous 
agonist of mGluRs. As a result, these compounds also act at the same binding pocket as 
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glutamate, the N-terminal Venus Flytrap domain of mGluRs. Targeting the orthosteric 
glutamate binding site has been successful for generating many groups of non-selective 
or selective compounds for mGluRs, which have been useful in demonstrating the 
pharmacological properties and physiological roles of mGluRs in both recombinant and 
native systems (Schoepp et al., 1999).  
 
1. Orthosteric ligands of mGluRs.  
Quisqualic acid (quisqualate) is the first identified agonist for phosphoinositide 
linked mGluRs. It has sub-micromolar potencies at group 1 mGluRs in both native and 
recombinant systems (Palmer et al., 1988). However, its use as a group I mGluR-
selective agonist is limited by its activity at mGluR3 and AMPA receptors (Watkins et al 
1990; Scheopp et al., 1999). The first selective agonist for mGluRs was 
aminocyclopentane-trans-1,3-dicarboxylic acid (trans-ACPD), which is a 
conformationally restricted glutamate analog that activates multiple mGluRs but does not 
activate iGluRs (Desai and Conn, 1991; Palmer et al., 1989). Thus it was used widely to 
study mGluR functions both in vitro and in vivo. However, because it activates almost all 
mGluR subtypes (except mGluR7) with a similar potency, its use is also limited. 3,5-
Dihydroxyphenylglycine (DHPG) is the first group 1-selective mGluR agonist. It is 
active to both recombinant and native group 1 mGluRs but displays no agonist or 
antagonist activity to other groups of mGluRs (Schoepp et al., 1994). DHPG has been 
used widely to investigate the pharmacological properties and physiological roles of 
group 1 mGluRs in many studies. For example, bath application of DHPG has been 
shown to have variety of physiological effects in hippocampal CA1 pyramidal neurons, 
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including direct depolarization, increasing of cell firing, decreasing of γ-aminobutyric 
acid (GABA)-mediated inhibition, potentiation of NMDAR current and intracellular 
calcium increase (Mannaioni et al., 2001). In addition, DHPG activates group 1 mGluRs 
to induce a chemical form of long term depression (LTD) at the Schaffer collateral CA1 
synapse (Palmer et al., 1997). Other group selective agonists have also been identified but 
none of them achieves subtype selectivity among all the mGluRs (Schoepp et al., 1999). 
(RS)-2-chloro-5-hydroxyphenylglycine (CHPG) is a mGluR5 selective agonist but has 
very weak potency and efficacy (Doherty et al., 1997). 
 
2. Importance of developing novel mGluR ligands.  
Initial efforts to develop inhibitors of mGluRs, which also focused on the 
glutamate binding site, have identified a variety of competitive antagonists for mGluRs. 
However, similar to agonists acting at the glutamate site, these competitive antagonists 
are not able to achieve good selectivity for specific mGluR subtypes (Schoepp et al., 
1999). Thus it has been proposed that because the glutamate binding pockets are 
relatively highly conserved among all the eight family members of mGluRs due to the 
evolutionary pressure of glutamate binding, the chance is low to develop subtype-
selective compounds acting at the glutamate binding pockets of mGluRs. It is clear that 
different subtypes of mGluRs exist in the same neurons through out the CNS. For 
example, immunocytochemistry studies reveal that mGluR5 is localized in CA1 
pyramidal cells, but not mGluR1a (Baude et al., 1993; Romano et al., 1995). Therefore, 
mGluR5 was thought to be the group 1 mGluR that regulates CA1 pyramidal neurons. 
However, although mGluR5 is the most abundant group I mGluR in CA1 pyramidal cells, 
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these cells also express mGluR1 mRNA (Shigemoto et al., 1992; Berthele et al., 1998), 
and a follow-up immunohistochemical study with antibodies that react with all splice 
variants of mGluR1 indicated some mGluR1 immunoreactivity in this region (Ferraguti et 
al., 1998). Although the short forms of mGluR1 and mGluR5 are both primarily coupled 
to the same G α q/11 second messenger system, it is still possible that they may elicit 
distinct physiological effects in the same cells because of different activation kinetics and 
coupling to different effector systems as well as different expression levels (Pin et al., 
1992; Kawabata et al., 1996; Conn and Pin, 1997). Hence, it is important to develop 
subtype selective mGluR agonists and antagonists to demonstrate the distinct roles of 
different subtypes of mGluRs.  
 
3. Novel non-amino acid mGluR antagonists.  
In the late 1990s, the first generation of the non-amino acid class of mGluR 
antagonists  was developed, among which, N-phenyl-7-
(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) and 
cyclopropan[b]chromen-1a-carboxylic acid ethylester (CPCCOEt) were characterized as 
mGluR1 selective antagonists compared with mGluR5, other groups of mGluRs and 
iGluRs (Annoura et al., 1996). CPCCOEt has no effect on mGluR2 or iGluRs. At a 
concentration much higher than its potency on mGluR1, CPCCOEt also blocks mGluR5 
mediated response. However, at certain concentrations, it is possible for these compounds 
to achieve selective blockade of mGluR1 without acting on mGluR5.  
CPCCOEt is a non-competitive mGluR1 antagonist. The non-amino acid origin of 
CPCCOEt led to a hypothesis that it may bind to a different site on mGluR1 instead of 
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the orthosteric glutamate binding pocket. This hypothesis has been supported by a series 
of studies. Classic amino-acid-like mGluR antagonists block mGluR responses 
competitively. In the absence of receptor reserve, competitive antagonists induce a 
parallel shift of the concentration response curve (CRC) of agonist to the right without 
reducing the maximal response. This kind of effect is obtained by the study of mGluR1 
competitve antagonist (S)-α-methyl-4-carboxyphenylglycine ((S)-MCPG) (Hermans et al., 
1998). Interestingly, CPCCOEt decreases the maximal response of the quisqualate CRC 
to a saturated plateau, which could not be reversed by increased concentration of 
quisqualate (Hermans et al., 1998).  This indicates that CPCCOEt is a non-competitive 
antagonist of mGluR1, which might interact at a site completely distinct from the 
glutamate binding pocket. This is additionally supported by a study showing that 
CPCCOEt does not displace specific [3H]quisqualate binding to cell membranes 
containing mGluR1 proteins (Okamoto et al., 1998).  
CPCCOEt acts at the seven TM domains of mGluR1. In order to identify the site 
of action of CPCCOEt, a series of mutagenensis and chimeric receptor studies were 
performed.  These studies were guided by the selectivity of CPCCOEt for mGluR1 
relative to mGluR5. Thus, the switching of crucial residues in mGluR1 to their 
corresponding residues of mGluR5 should reduce the antagonism by CPCCOEt. By this 
strategy, two amino acids (Thr815 and Ala818) were identified to be responsible for the 
selective action of CPCCEOt (Litschig et al., 1999). These two residues are located at the 
extracellular surface of TM domain VII. In conclusion, these non-competitive antagonists 
act at a distinct site from glutamate binding site. This opens up a novel way to develop 
subtype selective compounds for mGluRs (Schoepp et al., 1999). 
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 Mutel and colleagues developed the first mGluR positive allosteric modulators 
(PAM) for rat mGluR1 (rmGluR1) (Mutel et al., 2001; Knoflach et al., 2001), which are 
non-amino acid compounds (Ro67-7476, Ro 01-6128 and Ro 67-4853). These 
compounds have no effect on their own but potentiate the action of agonists. It has been 
shown that these compounds are devoid of any enhancing effect at recombinant mGluR2, 
mGluR4, and mGluR8 by various functional models including GTPγ[35S] binding, 
[Ca2+]int imaging, and activation of G-protein-regulated inwardly rectifying K+ channels 
(GIRKs). Importantly, Ro 67-7476 and Ro 01-6128 do not enhance the glutamate-
induced GIRK current in mGluR5 receptor-expressing cells. Mutagenesis experiments 
revealed that mutations within the seven TM domains of mGluR1 could abolish the 
potentiation of these compounds (Knoflach et al., 2001). There is no significant effect of 
these compounds, up to 10 μM, on the binding of [3H]quisqualate to rat mGluR5 
(rmGluR5), whereas they increase the binding of this ligand to the rmGluR1a (Knoflach 
et al., 2001). However, the increased affinity in competition binding assay is smaller than 
the increase of quisqualate potencies caused by the same concentrations of these mGluR1 
PAMs (Knoflach et al., 2001). These results indicate that this novel family of mGluR1 
PAMs act through binding to the 7 TM domain of the receptor to potentiate the mGluR1 
response via a mechanism that enhances the agonist binding affinity, at least partially, to 
the receptor. The discovery of non-competitive mGluR antagonists and PAMs leads to 
the conclusion that there could be both negative and positive allosteric modulators acting 
on the 7 TM domains of mGluRs. The non-competitive antagonists of mGluRs are also 
called negative allosteric modulators (NAM) in contrast to PAMs. 
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4. Advantages of mGluR allosteric compounds.  
Compared to classic orthosteric compounds, allosteric modulators could display 
better subtype selectivity among mGluR subtypes. This result provides a solution for the 
difficulty in developing potent subtype selective compounds targeting the orthosteric 
glutamate binding site. Additionally, classic orthosteric compounds have difficulty 
crossing the blood brain barrier (BBB) because their general hydrophilicity due to their 
amino acid origins. Thus, their usage is limited to in vitro studies. In contrast, the mGluR 
allosteric modulators are usually hydrophobic and theoretically should exhibit better 
penetration of BBB. Moreover, derivatives of amino acids are often easily metabolized; 
hence the non-amino acid nature of mGluR allosteric modulators could have more 
favorable pharmacokinetics.  In conclusion, mGluR allosteric modulators have improved 
subtype selectivity, BBB penetration and pharmacokinetics compared with classic 
mGluR orthosteric compounds. These properties will allow these novel compounds to be 
used as better pharmacological tools for basic studies of mGluRs as well as potentially 
useful therapeutic reagents. Thus a lot of effort has been focused on the development and 
characterization of novel mGluR allosteric modulators. My graduate research has been 
focused on studies of the pharmacological properties and the physiological effects of 
mGluR5 PAMs. 
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Metabotropic Glutamate Receptor Subtype 5 
 
Molecular identity, structure and signaling.  
mGluR5 belongs to the group 1 mGluRs which primarily couple to Gα q/11 
signaling pathway. It is the most abundant mGluR and is expressed in many regions of 
mammalian CNS. There are two splice forms of mGluR5, mGluR5a and mGluR5b. The 
N-terminal domain and the heptahelical domain of the two splice isoforms are identical, 
but mGluR5b has an additional insertion of a 32 amino acids fragment after the fiftieth 
residue of the C-terminal tail (Joly et al., 1995). Both isoforms contain a long 
intercellular C-terminal tail of more than 300 residues, which is the target of many 
interactinG-proteins. For instance, the Homer proteins have been shown to interact with a 
Pro-Pro-X-X-Phe-Arg (PPXXFR) motif close to the C-terminus (Xiao et al., 2000). 
These proteins can therefore link mGluRs to large protein complexes and control many 
aspects of receptor function, such as membrane insertion, localization, kinetics of the 
intracellular calcium signal, and constitutive activity (Roche et al., 1999; Ango et al., 
2000; Tu et al., 1998; Ango et al., 2001). In addition to coupling to phospholipase C 
through Gq/11, mGluR5 also activates other signaling pathways. For example, mGluR5 
activation increases extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation 
in cultured rat cortical astrocytes. This activation requires transactivation of the epidermal 
growth factor receptor but not phospholipase C activation (Peavy et al., 2001, 2002). This 
epidermal growth factor receptor-dependent ERK phosphorylation and phospholipase C-
dependent responses are differentially regulated by protein kinase C, although they are 
both initiated by activation of mGluR5 (Peavy et al., 2002).  
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mGluR1 and mGluR5 mediate different physiological responses when co-existing in 
the same cell population.  
 
Both mGluR1 and mGluR5 are abundantly expressed in many neuronal 
populations, including those in the hippocampus, subthalamic nucleus (STN), substantia 
nigra, globus pallidus and other forebrain and midbrain regions (Awad et al., 2000; Poisik 
et al., 2003; Wittmann et al., 2001). Our group has examined the physiological roles of 
mGluR1 and mGluR5 in multiple neuronal populations including hippocampal CA1 
pyramidal cells, STN neurons, substantia nigra neurons and globus pallidus neurons.  
Interestingly, in each cell population from which we have recorded, we find that mGluR1 
and mGluR5 have distinct effects (Valenti et al., 2002).   In addition, the precise role of 
each group I mGluR subtype is cell-type specific.   
While mGluR1 and mGluR5 are closely related and couple to the same G-proteins 
and effector systems in cell lines, it is clear that these receptor subtypes do not usually 
have redundant effects in native preparations, but often couple to distinct 
electrophysiological responses (Valenti et al., 2002). For instance, selective group 1 
mGluR agonist DHPG induces a robust increase in intracellular calcium as measured by 
an increase in fluorescence in cells loaded with the calcium-sensitive fluorescent dye 
Fluo3 and an inward current that leads to cell depolarization when recording in current 
clamp mode in CA1 pyramidal cells (Mannaioni et al., 2001).  Interestingly, both of these 
responses were completely blocked LY367385, a competitive antagonist that is selective 
for mGluR1.  In contrast, neither response is blocked by 2-methyl-6-(phenylethynyl) 
pyridine (MPEP), a noncompetitive antagonist that is selective for mGluR5 (Mannaioni 
et al., 2001).   This result is surprising and suggests that although mGluR5 is heavily 
expressed in these cells, only mGluR1 is involved in eliciting the somatic calcium 
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transient and inward current.  However, DHPG also elicits a number of other responses in 
these cells, including inhibition of multiple potassium currents and changes in synaptic 
transmission.  For instance, DHPG induces a complete inhibition of a slow calcium-
activated potassium current termed IAHP. In contrast to the effect on calcium transients 
and the inward current, DHPG-induced suppression of IAHP is not blocked by LY367385 
but is completely blocked by the mGluR5-selective antagonist MPEP, suggesting that this 
response is exclusively mediated by mGluR5 (Mannaioni et al., 2001).  Similarly, MPEP, 
but not LY367385 blocks DHPG-induced potentiation of the NMDA receptor current 
(Mannaioni et al., 2001).  Thus, while mGluR1 and mGluR5 can both couple to similar 
signal transduction mechanisms (i.e. Gq and activation of PLC), these receptors can have 
clearly distinct effects when present in the same hippocampal CA1 pyramidal neuron 
population.  
Similar results have been shown in other neuron populations. Electrophysiology 
studies have revealed that the group I mGluR agonist DHPG induces a depolarization of 
STN neurons and potentiates NMDA receptor currents (Awad et al., 2000).  Both the 
depolarization and the increase in NMDA receptor currents are completely blocked by 
the mGluR5 antagonist MPEP but not by the selective mGluR1 antagonists LY367385 or 
CPCCOEt (Awad et al., 2000).  Thus, while both mGluR1 and mGluR5 are abundantly 
expressed, DHPG–induced depolarization and potentiation of NMDA receptor currents 
are mediated exclusively by mGluR5. Interestingly, either the mGluR1-selective 
antagonist LY367385 or the mGluR5 antagonist MPEP completely blocks the DHPG-
induced calcium response (Marino et al., 2002).  These intriguing results suggest that 
while mGluR5 activation alone is necessary and sufficient to elicit depolarization and 
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potentiation of NMDA receptor currents, neither mGluR1 nor mGluR5 alone can elicit a 
detectable somatic calcium transient response; only co-activation of both receptors with 
DHPG elicits a robust response. In GABAergic projection neurons of the substantia nigra 
pars reticulata (SNr), DHPG-induced depolarization is mediated exclusively by mGluR1.  
This is in clear contrast to the role of mGluR5 in depolarization of STN neurons.  
However, in common with STN neurons, either LY367385 or MPEP blocks the somatic 
calcium transient, suggesting that both receptor subtypes are functionally active (Marino 
et al., 2002).  
Group 1 mGluRs are also activated via synaptic transmission. In most cases, these 
receptors are involved in slow mGluR-mediated synaptic responses consistent with 
responses to exogenous agonists, such as the slow synaptic responses of GABAergic 
projection neurons in the SNr and a dopamine neuron in the substantia nigra pars 
compacta (SNc) to stimulation of glutamatergic afferents. In SNr neurons, stimulation of 
excitatory afferents elicits a depolarization with increased action potential firing (Marino 
et al., 2001).  In contrast, for dopamine neurons, stimulation of glutamatergic afferents 
induces a slow hyperpolarization (Fiorillo and Williams, 1998; Marino et al., 2001).  In 
both cases, the response is mediated exclusively by mGluR1 and completely blocked by 
the mGluR1 antagonists LY367385 or CPCCOEt, but not by MPEP (Marino et al., 2001; 
Ciombor et al., 2002).   
 
mGluR5 is a potential target for novel therapeutic agents for the treatment of  
schizophrenia.  
 
Recent studies revealed mGluR5 as a potential drug target for agents that may 
provide better treatment of schizophrenia. Schizophrenia is a prevalent chronic 
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psychiatric disorder, affecting 1% of the population worldwide. This disorder is 
characterized by a combination of negative and positive symptoms as well as cognitive 
impairments. However, the etiology remains unknown. Traditional dopamine D2 receptor 
blocker therapeutics have several obvious shortcomings. They normally do not have any 
effect on about 25% of the treated patients and are often unable to relieve the negative 
symptoms and cognitive deficits and can elicit a variety of severe side effects.  Atypical 
antipsychotic drugs have shown some improvement in the relief of all the symptoms. 
However, their efficacy in the treatment of negative symptoms and cognitive impairment 
is low and severe side effects still remain a problem. The large affected population, lack 
of effective therapeutics and relatively early onset lead to a tremendous amount of money 
($20 to 35 billion annually) spent on schizophrenia in the United States alone (Marino et 
al., 2002; Chavez-Noriega et al., 2002). 
Recent clinical and basic studies suggest that changes in signaling through the 
NMDA subtype of glutamate receptor may play an important role in some of the 
pathological changes associated with schizophrenia (Coyle et. al., 2002; Marino and 
Conn, 2002a; Tsai and Coyle 2002). For instance, NMDA receptor antagonists, 
phencyclidine (PCP) and ketamine, produce cognitive deficits and positive and negative 
symptoms in normal human volunteers that are reminiscent of those observed in 
schizophrenic patients.  In addition, these agents exacerbate existing symptomatology in 
schizophrenic patients.  Furthermore, administration of agents that enhance NMDAR 
function, such as agonists at the glycine binding site on the receptor, results in a 
symptomatic improvement in schizophrenic patients. Also, NMDA co-agonists are able 
to relieve all the positive and negative symptoms as well as cognitive deficits in 
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schizophrenic patients (Tsai et al., 1998). Recently, the broad benefits of clozapine, an 
atypical antipsychotic drug, have been correlated with its indirect capability to enhance 
NMDA receptor activity via one of its main metabolites (Sur et al., 2003; Weiner et al., 
2004). An NMDA hypofunction model of schizophrenia has been developed based on 
these observations (Marino et al., 2002). Therefore, it is predicted that any drug that 
enhances NMDA receptor activity should have the potential to treat schizophrenia 
(Marino et al., 2002).  
Several approaches have been taken to potentiate NMDA receptor function by 
activation of either NMDA receptor itself or NMDA receptor regulatory proteins, such as 
mGluR5. mGluR5 is primarily localized postsynaptically, where it potentiates NMDA 
receptor currents in a wide range of neuronal populations. One possible mechanism for 
mGluR5 to enhance NMDA receptor activity is that G-protein activation of PLC in turn 
activates PKC (protein kinase C) and SFK (src family kinase) via multiple 2nd messenger 
system components. SFK in turn up-regulates NMDA receptor function (Salter and Kalia, 
2004; Chavez-Noriega et al., 2002; Benquet et al., 2002). A number of recent studies 
suggest that mGluR5 is a closely associated signaling partner with the NMDA receptor 
and may play an integral role in regulating and setting the tone of NMDA receptor 
function in a variety of forebrain regions (Marino and Conn, 2002a).  Based on this and a 
large number of cellular studies suggesting that activation of mGluR5 could have robust 
effects in forebrain circuits thought to be disrupted in schizophrenia, we and others 
postulated that activators of mGluR5 could provide novel therapeutic agents that may be 
useful for treatment of this disorder (Marino and Conn, 2002a; Mohgaddam et al., 2004). 
Consistent with this, other evidence has emerged that suggests a possible involvement of 
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mGluR5 in schizophrenia. A genetic study of a large Scottish family successfully links an 
mGluR5 variation with high risk of schizophrenia (Devon et al., 2001). Behavioral 
studies also demonstrate that MPEP is able to potentiate hyperactivity, disruption in pre-
pulse inhibition (PPI) and cognitive deficits in the PCP-induced schizophrenia rat model. 
In addition, mGluR5 knock-out mice display consistent deficits in PPI relative to their 
wildtype controls (Kinney et al., 2003b; Henrey et al. 2002; Campbell et al., 2004; Brody 
et al., 2004). Moreover, CHPG, an mGluR5 selective agonist, reverses amphetamine-
induced disruption of PPI in rat (Kinney et al., 2003). Taken together, mGluR5 selective 
activators may have promise as novel potential therapeutic agents for schizophrenia.  
 
mGluR5 is a potential target for multiple other neuronal and psychiatric disorders.  
Hyperactivity of the STN has long been associated with some of the hallmark 
symptoms of Parkinson's disease (PD) (DeLong, 1990). In the STN, mGluR5 mediates 
excitatory effects (Awad et al., 2000). Thus, it is possible that blockade of mGluR5 
activity in the STN could be beneficial in treating PD pathophysiology. Additionally, 
globus pallidus (GP) neurons send inhibitory projections to the STN and MPEP 
potentiates the mGluR1-mediated depolarization of GP neurons. MPEP could exert an 
anti-parkinsonian effect by facilitating the mGluR1-mediated increased activity of the 
pallidosubthalamic pathway (Poisik et al., 2003).  Consistent with this, there are reports 
demonstrating that systemic administration of MPEP ameliorates parkinsonian-like 
symptoms in rodent models of the disease (Ossowska et al., 2001; Spooren et al., 2001). 
Moreover, studies with mGluR5 selective antagonists, MPEP and MTEP, suggest that 
mGluR5 may be involved in the physiological and pathological responses related to 
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neurodegeneration, depression, anxiety, epilepsy, pain, and drug addiction (Chapman et 
al., 2000; Palucha A and Pilc A, 2002; Chojnacka-Wojcik et al., 2001; Lea et al., 2006). 
Further studies are necessary to refine our understanding of the roles of mGluR5 in these 
disorders and to evaluate the possibility that selective blockade of mGluR5 could be used 
as potential strategy for their treatment. 
 
mGluR5 is a potential target for learning and memory enhancing reagents.  
Plasticity of synaptic transmission has been proposed to be the molecular corelates of 
learning and memory. Long term potentiation (LTP) and long term depression (LTD) are 
two basic forms of synaptic plasticity. Activation of mGluR5 has been suggested to be 
essential for the induction of synaptic plasticity including both LTP and LTD in the 
hippocampal CA1 region. mGluR5 knockout mice have impaired LTP in the 
hippocampal CA1 region and show impairments in memory tasks, such as the Morris 
water maze and contextual information in the fear-conditioning test (Lu et al., 1997). 
Also, the mGluR5 selective antagonist MPEP blocks theta burst stimulation (TBS)-
induced LTP in the rat CA1 region (Francesconi et al., 2004; Shalin et al., 2006). 
Meanwhile, the group 1 mGluR selective agonist DHPG has been reported to prime LTP 
induction at relatively low concentrations (Cohen et al., 1998; Raymond et al., 2000) and 
induce LTD at higher concentrations in the CA1 region (Gasparini et al. 1999; Huber et 
al., 2001). DHPG-induced LTD is absent in mGluR5 null mice and can be blocked by 
MPEP (Faas et al. 2002; Gasparini et al. 1999; Hou and Klann 2004; Huang and Hsu 
2006; Huang et al. 2004 and Huber et al., 2001). Moreover, low frequency stimulation 
(LFS) also induces an mGluR-dependent LTD in addition to NMDAR dependent LTD 
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(Oliet et al., 1997). Thus it has been postulated that certain manipulations of mGluR5 
could affect cognition performance of mammals.  
 
Allosteric modulators of mGluR5.  
 
1. Non-competitive antagonist - MPEP.  
MPEP is one of the earliest allosteric modulators of mGluR5, which is a highly 
selective full antagonist with nanomolar potency (Gasparini et al., 1999). Schild analysis 
indicates that MPEP acts on mGluR5 in a non-competitive manner (Pagano et al., 2000). 
MPEP also inhibits the constitutive receptor activity in cells transiently overexpressing 
mGluR5, suggesting that MPEP is an inverse agonist. A mutagenesis study using both 
chimeras and single amino acid substitutions of human mGluR1 and human mGluR5 has 
been successful to show the molecular determinants of MPEP action and binding. The 
studies with chimeric receptors show that TM3 and TM7 are two critical domains for the 
selective inhibitory effect on mGluR5 compared with mGluR1 (Pagano et al., 2000). 
Replacement of Ala810 in TM7 or Pro655 and Ser658 in TM3 with the homologous 
residues of mGluR1 abolishes radiolabeled ligand binding to the MPEP site (Pagano et al., 
2000). In addition, a reciprocal mGluR1 mutant bearing these three residues of mGluR5 
shows high affinity for radio-labeled MPEP analog (Pagano et al., 2000). These results 
were confirmed by a different group in rat mGluR5 (Malherbe et al., 2003). MPEP has 
been widely used to study the physiological and behavioral roles of mGluR5 compared 
with mGluR1 (Lea et al., 2006). 
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2. DFB, DCB and DMeoB.  
The success of MPEP stimulated the search for positive allosteric modulators of 
mGluR5. The first mGluR5 PAM is difluorobenzaldazine (DFB) (O’Brien et al., 2003).  
DFB has no effect on mGluR5 mediated response alone, but shifts the concentration 
response curve of glutamate and other orthosteric agonists to the left (Figure 1-3A).  DFB 
is highly selective for mGluR5 and has no activity at other mGluR subtypes (O’Brien et 
al., 2003).  DFB does not alter binding of [3H]quisqualate to the orthosteric glutamate 
binding site but displaces radioligand binding to the binding site of the allosteric 
antagonist MPEP, suggesting that this allosteric potentiator might share the same site 
with the previously identified NAMs of mGluR5 (O’Brien et al., 2003). A series of 
analogs of DFB have been developed to have a range of activities. While DFB is a PAM, 
a closely related analog, 3,3'-dimethoxybenzaldazine (DMeOB), is a NAM of mGluR5. 
Another DFB analog 3,3'-dichlorobenzaldazine (DCB) acts as an allosteric ligand with 
neutral cooperativity, preventing the positive allosteric modulation of mGluR5 by DFB as 
well as the negative modulatory effect of DMeOB. Similar to DFB, neither DMeOB nor 
DCB alters binding of [3H]quisqualate to the orthosteric glutamate site, but they reduce 
[3H]3-methoxy-5-(2-pyridinylethynyl)pyridine ([3H]MethoxyPEPy) binding to the 
allosteric MPEP site (Figure 1-3B). These interesting results suggest that structurally 
related compounds can bind to a single allosteric site to exert effects ranging from 
negative to positive as well as neutral allosteric activities (O’Brien et al., 2003).   
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Figure 1-3: DFB family of mGluR5 allosteric modulators. A. Structure of DFB and its 
role to dose dependently potentiated glutamate concentration dose response curve 
using calcium mobilization assay of mGluR5 expressing cells. B. DFB, DCB and 
DMeOB reduced [3H]MethoxyPEPy binding to mGluR5 expressing membrane. 
(Modified from O'Brien et al., 2003) 
 
 
3. CPPHA  
Recently, a second class of mGluR5 PAMs represented by N-{4-chloro-2-[(1,3-
dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl] phenyl}-2-hydroxybenzamide (CPPHA) has 
been discovered (O’Brien et al., 2004).  Similar to DFB, CPPHA has no effect on 
mGluR5 alone and does not alter [3H]quisqualate binding to the orthosteric gulatmate site, 
but shifts the glutamate concentration response curve to the left (O’Brien et al., 2004).  
CPPHA is more potent that DFB (EC50 = 100 nM) and induces more robust shift in the 
glutamate concentration response curve.   Interestingly, CPPHA does not compete with 
ligand binding to the MPEP binding site (Figure 1-4).  These data suggest that mGluR5 
PAMs may act at multiple sites and have multiple mechanisms of the action. It also 
suggests that CPPHA and DFB act at different sites on the receptor to potentiate mGluR5 
mediated responses. Alternatively, this data suggests that DFB might bind to multiple 
sites on mGluR5: the MPEP site is one of these sites DFB acts at, but it is not the site that 
is required for DFB to potentiate mGluR5 responses.   
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Figure 1-4: CPPHA does not bind to MPEP site. Membranes prepared from human 
mGluR5 CHO cells were incubated with the radiolabeled MPEP analog 
[3H]MethoxyPEPy. (Modified from O'Brien et al., 2004) 
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4. CPPHA and DFB differentially regulate mGluR5-mediated ERK phosphorylation.  
Recently, increasing evidence suggests that different agonists could differentially 
activate different signaling pathways of a single GPCR, a phenomenon termed agonist 
receptor trafficking (Brink et al., 2000; Gazi et al., 2003; Berg et al., 1998).  Based on 
this, it is possible that PAMs of mGluRs could differentially regulate different signaling 
pathways coupled to a single mGluR subtype. mGluR5 has been shown to couple to 
multiple signaling pathways and physiological responses.  For example, in secondary 
cultured rat cortical astrocytes, mGluR5 activates PI hydrolysis and extracellular signal 
regulated kinase (ERK2) phosphorylation by completely independent mechanisms (Peavy 
et al., 2001; 2002).  Both DFB and CPPHA induce parallel leftward shifts of the 
concentration-response curves of DHPG- and glutamate-induced calcium transients in 
secondary cultured rat cortical astrocytes. DFB induced a similar shift of concentration-
response curve of DHPG-induced ERK1/2 phosphorylation (Zhang et al., 2005). 
However, CPPHA induces an increase in basal mGluR5-mediated ERK1/2 
phosphorylation and potentiates the effect of low concentrations of agonists. In contrast, 
CPPHA significantly decreases ERK1/2 phosphorylation induced by high concentrations 
of DHPG. Thus, CPPHA has qualitatively different effects on mGluR5-mediated calcium 
responses and ERK1/2 phosphorylation (Zhang et al., 2005). Together, these data suggest 
that different PAMs could differentially modulate different signaling pathways coupled to 
a single receptor.  
It has been found that activation of mGluR5 can have a wide variety of effects on 
different neuronal populations, including cell depolarization, modulation of different 
potassium currents, potentiation of NMDA receptor currents, and a variety of other 
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responses (Valenti et al., 2002). It is possible that these responses are mediated by 
different signaling mechanisms and could be differentially regulated.  In addition, in 
many neuronal populations, both mGluR1 and mGluR5 are co-expressed, but they elicit 
different responses (Valenti et al., 2002; Marino et al., 2002; Awad et al., 2000; Poisik et 
al., 2003; Mannaioni et al., 2001). Since mGluR1 and mGluR5 are closely related in 
terms of G-protein coupling, this raises the possibility that PAMs could induce a 
qualitative change in the physiological impact of activation of these receptors in some 
neuronal populations.  Thus it becomes critical to determine how different PAMs could 
differentially regulate the different signaling responses coupled to a single receptor. One 
possibility is that DFB and CPPHA could elicit their distinct effects on ERK1/2 
phosphorylation by acting at the different sites of mGluR5. This question remains largely 
unaddressed.  
 
5. CDPPB.  
The discovery of DFB and CPPHA represents a major advance in establishing the 
utility of developing selective PAMs at a cellular and molecular level.  However, these 
compounds have relatively low potency and inadequate pharmacokinetic properties 
needed for in vivo studies.  More recently, a third series of PAMs of mGluR5 has been 
identified (Lindsley et al., 2004). These compounds are suitable for in vitro studies in rat 
brain slices and in vivo studies to test the hypothesis that mGluR5 PAMs will have an 
antipsychotic-like and cognition-enhancing activity in animal models (Kinney et al., 
2005).  These compounds are represented by 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-
yl)benzamide (CDPPB).  CDPPB induces a robust potentiation of mGluR5 mediated 
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responses with an EC50 about 25 nM.  At 1 µM, CDPPB shifts mGluR5 agonist 
concentration response curves 9-fold to the left.  As with DFB and CPPHA, CDPPB has 
no effect on agonist binding to the orthosteric agonist binding site of mGluR5 and is 
highly selective for mGluR5 and has no effect on any other mGluR subtype.  
Furthermore, the activity of CDPPB was tested against a panel of 175 receptors, 
transporters, ion channels and enzymes and had no sub-micromolar activities at any of 
these known receptors (Kinney et al., 2005).   The increased potency and solubility of 
CDPPB relative to DFB and CPPHA make this compound highly suitable for 
electrophysiology studies in rat brain slices.  Furthermore pharmacokinetic studies in 
Sprague-Dawley rats reveal that CDPPB (2 mg/kg in DMSO) has a plasma half-life of 
4.4 hours and readily crosses the blood brain barrier (Kinney et al., 2005).  Thus, while 
CDPPB behaves in a manner similar to DFB and CPPHA at a cellular level, this 
compound represents a major advance relative to the previous compounds in that its 
properties make it highly useful for electrophysiology studies in brain slices and for 
determination of the behavioral effects of mGluR5 potentiators in vivo. As discussed 
above, previous anatomy, electrophysiology, and behavioral studies with mGluR5 
antagonists have led to the hypothesis that activation of mGluR5 could have behavioral 
effects in animal models that are used to predict antipsychotic and cognition-enhancing 
activity. Interestingly, CDPPB is found to be brain penetrant and to reverse 
amphetamine-induced locomotor activity and amphetamine-induced deficits in prepulse 
inhibition in rats, two models sensitive to antipsychotic drug treatment (Kinney et al., 
2005). These results demonstrate that positive allosteric modulation of mGluR5 produces 
significant behavioral effects, suggesting that such modulation serves as a viable 
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approach to increasing mGluR5 activity in vivo. These effects are consistent with the 
hypothesis that allosteric potentiation of mGluR5 might be a novel approach for 
development of antipsychotic agents. 
 
6. 5MPEP and partial antagonists.  
It has been reported that three novel MPEP analogs bind to the allosteric MPEP 
site on mGluR5 but have only partial inhibition or no functional effects on the mGluR5 
response. Two of these compounds, 2-(2-(3-methoxyphenyl)ethynyl)-5-methylpyridine 
(M-5MPEP) and 2-(2-(5-bromopyridin-3-yl)ethynyl)-5-methylpyridine (Br-
5MethoxyPEPy), act as partial antagonists of mGluR5 because they only partially inhibit 
the response of this receptor to glutamate. The third compound, 5-methyl-6-
(phenylethynyl)-pyridine (5MPEP), has no effect on mGluR5 mediated responses alone 
but still fully displaces MPEP site binding. Interestingly, 5MPEP blocks the effects of 
both the allosteric antagonist MPEP and allosteric potentiators CDPPB, similar to DCB’s 
effects on DFB and DMeoB. Importantly, 5MPEP has better potency and solubility than 
DCB. Furthermore, electrophysiological studies show that 5MPEP is active in brain 
slices preparations. Schild analysis using 5MPEP shows that 5MPEP inhibits MPEP 
antagonism via a competitive manner. It has been concluded that 5MPEP is a neutral 
mGluR5 allosteric modulator at the MPEP site, which provides a unique tool to study the 
pharmacological properties and physiological roles of mGluR5 allosteric modulators in 
both recombinant and native systems. 
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N-terminal truncated mutant of mGluR5.  
Interestingly, it has been shown that mGluR5 retains its constitutive activity on 
phosphoinositide hydrolysis (PI hydrolysis) with truncation of its N-terminal domain, 
including the orthosteric glutamate binding site, in recombinant systems. Interestingly, 
this constitutive activity is inhibited by the mGluR5 NAM, MPEP. Furthermore, this N-
terminal truncated mutant is able to be activated by the mGluR5 PAM, DFB, when it is 
expressed in the recombinant cell line systems (Goudet et al., 2004). This finding 
illustrates that, like Class 1 GPCRs, the heptahelical domain of mGluR5 can 
constitutively couple to G-proteins and be negatively and positively regulated by ligands. 
Furthermore, it provides insights into the unique activation mechanism of family 3 
GPCRs. The fact that PAMs do not directly activate wildtype mGluR5 but can activate 
the N-terminal truncated mutant suggests that there is an allosteric interaction between 
the Venus Flytrap glutamate binding domain and the heptahelical effector domain that 
controls the activation of the receptor. A conserved disulfide bond between these two 
domains has been shown to be necessary for this allosteric interaction which is consistent 
with this hypothesis (Ronard et al., 2006). Moreover, this discovery provides a unique 
tool to better understand the mechanism and pharmacological properties of PAMs. 
 
Objective of This Study 
The studies outlined above suggest the mGluR5 PAMs are useful tools to 
understand the mGluR5 physiological responses and can be used as potential reagents for 
the treatment of schizophrenia and other CNS disorders. However, the sites of action as 
well as other pharmacological properties of these compounds remain unclear.  
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According to the background studies, we hypothesized that CDPPB and CPPHA 
families of mGluR5 PAMs act through distinct sites in the receptor. CDPPB act at the 
same site as MPEP, while CPPHA acts at a different site. In chapter II of this thesis, a 
series of CDPPB analogs were synthesized and we found that they bound to the MPEP 
site with affinities that are closely related to their potencies as mGluR5 potentiators. 
Furthermore, allosteric potentiation was blocked by 5MPEP, the neutral ligand at the 
MPEP site and reduced by a mutation in mGluR5 that eliminates MPEP binding. 
Together, these data suggest that interaction with the MPEP site is important for allosteric 
potentiation of mGluR5 by CDPPB and related compounds. In addition, whole-cell 
patch-clamp studies in midbrain slices reveal that a highly potent analog of CDPPB, 4-
nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (VU-29), selectively potentiates 
mGluR5 but not mGluR1-mediated responses in midbrain neurons, whereas a previously 
identified allosteric potentiator of mGluR1 had the opposite effect.  
In chapter III of this thesis, we found that VU-29- and CPPHA-induced 
potentiation of mGluR5 responses were both blocked by 5MPEP.  However, increasing 
concentrations of 5MPEP induced parallel rightward shifts in the VU-29 concentration 
response curve (CRC) whereas 5MPEP inhibited CPPHA potentiation in a non-
ompetitive manner.  Consistent with this, one mutation that reduced binding of ligands to 
the MPEP site also eliminated the effect of VU-29 but had no effect on the response to 
CPPHA.  Conversely, a mutation (F585I/mGluR5) that eliminated the effect of CPPHA 
did not alter the response to VU-29.  CPPHA was also a PAM at mGluR1. Interestingly, 
the corresponding mutation of F585I/mGluR5 in mGluR1 (F599I/mGluR1) eliminated 
CPPHA’s effect without altering the potentiation of a known PAM of mGluR1 (Ro 67-
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7476).  Likewise, another mutation (V757L/mGluR1) abolished potentiation of Ro 67-
7476 had no effect on CPPHA.  Finally, CPPHA did not displace binding of a radioligand 
for the previously characterized mGluR1 allosteric antagonist.  Together, these data 
suggest that CPPHA acts at a novel allosteric site on group 1 mGluRs to potentiate their 
responses. 
There is evidence suggesting that mGluR5 may play a role in learning and 
memory, but its precise role is still unknown. Taking the advantage of the novel mGluR5 
PAMs, we hypothesize that mGluR5 PAMs could affect the plasticity of the rat 
hippocampal slices by enhancing mGluR5 activation. In chapter IV of this thesis, we test 
the effect of mGluR5 PAms on rat hippocampal LTP induction. Specifically, we found 
500 nM VU-29 potentiated DHPG-induced PI hydrolysis in hippocampal slices, which 
could be completely blocked by 5MPEP. 500 nM VU-29 did not affect basic synaptic 
transmission in the CA1 region. Interestingly, pre-incubation of VU-29 significantly 
enhanced threshold theta burst stimulation (TBS)-induced long term potentiation (LTP). 
This LTP induction was eliminated by NMDA receptor antagonist, D-AP5. The LTP 
enhancement was completely blocked by 5MPEP, which had no effect on 10 HZ TBS-
induced LTP. Additionally, saturated TBS-induced LTP occluded VU-29 facilitated LTP. 
VU-29 was not able to further enhance saturated TBS-induced LTP. These results 
indicate that VU-29 facilitated LTP shares the same mechanism with TBS-induced LTP.  
Meanwhile, ADX-47273, a novel mGluR5 selective PAM from a distinct structural 
family, also significantly facilitated threshold TBS-induced LTP. Thus, we conclude 
mGluR5 PAMs are able to facilitate threshold TBS-induced LTP in the rat hippocampal 
CA1 region, which could be used as potential cognition enhancing reagents. 
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In summary, we have investigated two distinct crucial sites action for two 
different families of mGluR5 PAMs respectively and their differential pharmacological 
properties. Additionally, we have reported the first evidence that mGluR5 PAMs have the 
potential to be cognition enhancing reagents by facilitating rat hippocampal CA1 LTP 
induction.  
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Table 1-1: Summary of mGluR ligands pharmacology. 
AllostericmGluR5Neutral Modulator5MPEP
AllostericmGluR5PAMVU-29
AllostericmGluR1AntagonistR214127
AllostericmGluR1PAMRo 67-7476
AllostericmGluR1PAMRo 67-4853
AllostericmGluR1PAMRo 01-6128
OrthostericiGluRs/mGluRsAgonistQuisqualate
AllostericmGluR1AntagonistPHCCC
AllostericmGluR5AntagonistMPEP
OrthostericmGluR1AntagonistLY367385
OrthostericmGluR4/6/7/8AgonistL-AP4
AllostericmGluR5AntagonistDMeOB
OrthostericmGluR1/5AgonistDHPG
AllostericmGluR5PAMDFB
AllostericmGluR5Neutral ModulatorDCB
AllostericmGluR1AntagonistCPCCOEt
AllostericmGluR1/5PAMCPPHA
AllostericmGluR5PAMCDPPB
AllostericmGluR5PAMADX-47273
Site of ActionSelectivityActivityCompound
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CHAPER II 
 
INTERACTION OF NOVEL POSITIVE ALLOSTERIC MODULATORS OF 
MGLUR5 WITH THE NEGATIVE ALLOSTERIC ANTAGONIST SITE IS 
REQUIRED FOR POTENTIATION OF RECEPTOR RESPONSES 
 
 
(This chapter was published in: Molecular Pharmacology 71:1389-1398, 2007) 
 
Introduction 
Glutamate is the major excitatory neurotransmitter in the mammalian CNS. In 
addition to eliciting fast excitatory synaptic responses, glutamate has important 
neuromodulatory effects by the activation of G-protein-coupled receptors (GPCRs) 
termed metabotropic glutamate receptors (mGluRs). The mGluRs play important roles in 
a broad range of central nervous system functions and have potential as novel targets for 
the development of new therapeutic agents for a number of neurological and psychiatric 
disorders, including Parkinson's disease (Marino and Conn, 2002b), epilepsy (Doherty 
and Dingledine, 2002), Alzheimer's disease (Wisniewski and Carr, 2002), pain (Varney 
and Gereau, 2002), schizophrenia (Marino and Conn, 2002a), depression (Palucha and 
Pilc, 2002), anxiety disorders (Chojnacka-Wojcik et al., 2001; Pilc, 2003), and others. 
Since the initial discovery of the mGluRs, there has been an increasing focus on 
developing subtype-selective modulators of these receptors for use as potential clinical 
agents and as pharmacological tools that could aid in developing a better understanding of 
mGluR function. 
Although mGluRs have a seven transmembrane (7TM)-spanning domain similar 
to other GPCRs (Conn and Pin, 1997; Bhave et al., 2003), glutamate binds these receptors 
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on a large N-terminal extracellular glutamate binding domain that is composed of two 
globular domains and a hinge region (O'Hara et al., 1993; Jingami et al., 2003). As 
expected for a region involved in binding a common endogenous agonist, the glutamate 
binding sites share high homology across the mGluR subtypes relative to other regions of 
the receptor (Conn and Pin, 1997). Based on this, we and others have begun to take a 
novel approach and develop compounds that interact with potentially less evolutionary 
conserved allosteric sites of mGluRs (Knoflach et al., 2001; Gasparini et al., 2002; 
Marino et al., 2003; May and Christopoulos, 2003; O'Brien et al., 2003, 2004; 
Schaffhauser et al., 2003). For instance, we have developed DFB, CPPHA, and CDPPB 
as three distinct structural classes of allosteric potentiators of mGluR5 (O'Brien et al., 
2003, 2004; Kinney et al., 2005). These compounds do not activate mGluR5 directly but 
potentiate the response of mGluR5 to glutamate, inducing a leftward shift of the 
glutamate concentration-response curve. It is noteworthy that these allosteric modulators 
do not affect binding of ligands to the orthosteric glutamate binding site. Thus, in contrast 
to known allosteric modulators of family A GPCRs, they do not act by altering agonist 
affinity. However, competition binding with [3H]methoxyPEPy, an analog of the 
allosteric mGluR5 antagonist MPEP, reveals that two potentiators, DFB and CDPPB, 
displace binding to this site. This led to the suggestion that allosteric potentiators and 
allosteric antagonists act at overlapping sites in the transmembrane domain. However, 
whereas CDPPB fully displaces [3H]methoxyPEPy binding, it is not clear whether this 
compound interacts competitively with [3H]methoxyPEPy at this site. Furthermore, the 
potency of CDPPB as an allosteric potentiator of mGluR5 is more than one magnitude 
higher than the apparent affinity of this compound at the [3H]methoxyPEPy site. Finally, 
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at least one mGluR5 allosteric potentiator, CPPHA, has been identified that does not 
displace [3H]methoxyPEPy binding (O'Brien et al., 2003, 2004; Kinney et al., 2005). 
Based on this, it is unclear whether the allosteric potentiator activity of CDPPB requires 
interaction with the site occupied by [3H]methoxyPEPy. In addition, the majority of 
studies that have been focused on characterizing mGluR5 potentiators have relied on 
cultured cell lines rather than native neuronal populations. Thus, it is unclear whether 
mGluR5 potentiators will selectively potentiate the regulation of mGluR5 neuronal 
excitability by native neurons. 
We report studies in which we use synthetic chemistry, along with molecular 
pharmacology approaches, to systematically examine the relationship between interaction 
of CDPPB and related compounds to the allosteric MPEP site and allosteric potentiator 
activity. Our studies suggest that activities of CDPPB and its analogs as allosteric 
potentiators are closely related to their affinities for the MPEP site. Furthermore, the 
discovery of an analog of CDPPB (VU-29) with low nanomolar potency provides an 
excellent tool for determining the effects of allosteric potentiators on excitation of 
neurons by mGluR5 and its closest relative, mGluR1. These compounds selectively 
potentiate mGluR5-mediated responses in midbrain slices without altering responses that 
are mediated by mGluR1. 
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Materials and Methods 
 
Mutagenesis and transient transfection. 
HEK 293A cells (Invitrogen, Carlsbad, CA) were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Invitrogen) containing 10% fetal bovine serum (FBS, 
Invitrogen), 1mM L-glutamine (Invitrogen) and 1× Antibiotic-Antimycotic (Invitrogen).  
Cells were collected and plated in clear-bottom-96-well plates (Costar, Corning Life 
Sciences) pretreated with poly-D-lysine (Sigma) in normal growth medium with a density 
of 40,000 cells per well overnight before transfection. Cells were transiently transfected 
with wild type and mutant forms of rat mGluR5a cDNA using the pRK5 vector (BD 
Biosciences Clontech, Palo Alto, CA). Point mutations were generated using the Quick 
Change II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA). All mutations 
were verified by sequencing. The transfection plasmid was prepared using Sigma Maxi 
Prep kit (Sigma-Aldrich, St Louis, MO). Cells were transfected with lipofectamine 
(Invitrogen) for 6 h according to the manufacturer’s instructions (80ng DNA and 0.2 l 　
lipofectamine per well) before switching to normal growth medium. Rat GLAST 
pCDNA3.1 (20 ng per well) was co-expressed with mGluR5 pRK5 to reduce 
extracellular glutamate concentration. Glutamate/glutamine free medium (glutamine free 
DMEM plus 10% dialyzed fetal bovine serum, Invitrogen) was applied to substitute 
growth medium at least 4 hours before performing functional assays. Cell culture, 
transfection and starving were performed at 37°C in an atmosphere of 95% air plus 5% 
carbon dioxide. Transfected cells were tested about 48 h after transfection. Rat mGluR2 
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and human mGluR4 were co-expressed with Gqi5 which enables coupling to the calcium 
mobilization as reported by Galici et al., (2006). 
 
Secondary rat cortical astrocytes culture. 
Secondary rat cortical astrocytes were prepared as described (Peavy et al., 2001; 
Zhang et al., 2005). Astrocytes were plated into poly-D-lysine coated 96-well plates with 
a density of 30,000 cells per well on day zero in DMEM containing 10% FBS, 1 mM L-
glutamine (Invitrogen) and 1× Antibiotic-Antimycotic (Invitrogen) for overnight. Then 
G-5 supplement (Invitrogen), which contains epidermal growth factor (10 ng/ml), basic 
fibroblast growth factor (5 ng/ml), insulin (5 µg/ml) and other factors, was added to the 
growth medium on day 1 and switched to glutamine-free DMEM with 10% dialyzed FBS 
on the day 3. Calcium mobilization assay was performed on the day 4. Cell culture and 
starving are were performed at 37°C with 5% carbon dioxide. 
 
Calcium fluorescence measurement. 
Cells were loaded with calcium-sensitive dye according to the manufacturer’s 
instructions (Calcium 3 kit; Molecular Devices Corp., Sunnyvale, CA) after incubated in 
glutamate/glutamine free medium (DMEM and 10% dialyzed fetal bovine serum) for five 
hours. 1 ml compound A from Calcium 3 kit was dissolved in 20 ml of 1× Hanks’ 
balanced salt solution (HBSS, Invitrogen/Gibco) containing 2.5 mM probenicid (Sigma), 
adjusted to pH 7.4. Cells were loaded for 50 min at 37°C with 5% carbon dioxide. Dye 
was then carefully removed and cells were washed with HBSS containing probenicid.  
Cells were maintained in the same buffer at room temperature for the following assay.  
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For calcium fluorescence measurement of rat cortical astrocytes, allosteric modulators 
were added 5 min before the addition of agonist manually. For transient transfected cells, 
allosteric modulators were added 1 min before the addition of agonist using Flexstation II 
(Molecular Devices Corp.). Agonist was added at a speed of 52 µl/s and Calcium flux 
was measured using Flexstation II at 25°C. All the peaks of the calcium response were 
normalized to the maximum response to a saturated dose of glutamate (10 µM). The 
submaximal concentration (EC20) of glutamate was determined for every separate 
experiment, allowing for a response varying from 10% to 30% of the maximum peak. 
 
Radioligand Binding Assays. 
The MPEP analog [3H]methoxyPEPy was used to test the binding of MPEP site 
on mGluR5 (Cosford et al., 2003). Membranes were prepared from stable rat mGluR5-
HEK293A cells (Rodriguez et al., 2005). [3H]methoxyPEPy were incubated with 
membrane (10 μg/well) in the binding buffer (50 mM Tris/0.9% NaCl, pH 7.4) with the 
presence or absence of CDPPB analogs at room temperature for 1 h with shaking. Then, 
the membrane-bound ligand was separated from free ligand by filtration through glass-
fiber 96 well filter plates (Unifilter-96, GF/B, PerkinElmer Life and Analytical Sciences, 
Boston, MA) and washed 3 times with binding buffer (Brandel Cell Harvester, Brandel 
Inc., Gaithersburg, MD). 30 μL scintillation fluid was added to each well and the 
membrane-bound radioactivity determined by scintillation counting (TopCount, 
PerkinElmer Life and Analytical Sciences).  Non-specific binding was estimated using 5 
μM MPEP. For Scatchard analysis, [3H]methoxyPEPy concentrations of 2.5, 5, 10, 20 
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and 40 nM were used, whereas 2 nM of [3H]methoxyPEPy was used for competition 
binding assay. The KD of [3H]methoxyPEPy by saturation binding was 3.4 nM. 
 
Compound preparation and application. 
5MPEP, CDPPB, VU-20 to VU-24, VU-28, VU-29, VU-35, and VU-36 were 
synthesized as described (Rodriguez et al., 2005; Lindsley et al., 2005; de Paulis et al., 
2006).  Compounds were dissolved in dimethyl sulfoxide (DMSO, Sigma) and stored at -
80ºC.  Stock solutions were dissolved in 1× HBSS containing 0.1% BSA (Albumin 
Bovine Serum, Sigma) on the day of experiment. Final DMSO concentration was 0.12% 
to 0.15% for all the assays.  
 
N-terminal truncated mGluR5 and Inositol Phosphate determination. 
Construction of the N-terminal truncated mutant of mGluR5 and inositol 
phosphate (IP) accumulation measurement were performed as reported by Goudet et al. 
(2004). Briefly, the mGluR5 mutant possesses the signal peptide of the wild-type 
mGluR5 followed by the HA epitope and the coding sequence of the 7TM region starting 
at P568, and terminating at L864. IP measurements were performed after transient 
transfection by electroporation of HEK 293a cells with the plasmid expressing the 
truncated mGluR5. The cells were incubated overnight with 3H-myoinositol (23.4 Ci/mol; 
NEN; France). Afterwashing, cells were stimulated with the indicated compounds for 30 
min in the presence of 10mM LiCl.  Inositol phosphate accumulated was recovered by 
ion exchange chromatography using a Dowex resin (Biorad) in 96 well microfilter plates. 
 41
Results are expressed as the ratio between IP and the total radioactivity (IP fraction plus 
the radioactivity in the membranes). 
 
Electrophysiology in Subthalamic Nucleus and Substantia Nigra Neurons. 
Whole cell recordings were performed using midbrain brain slices prepared from 
12 to 18 day old male Sprague–Dawley rats, as described (Awad et al., 2000; Marino et 
al., 2001). After decapitation, brains were rapidly removed and submerged in an ice-cold 
choline replacement solution containing 126 mM choline chloride, 2.5 mM KCl, 1.2 mM 
NaH2PO4, 1.3 mM MgCl2, 8 mM MgSO4, 10 mM glucose, and 26 mM NaHCO3, 
equilibrated with 95% O2, 5% CO2. Sagittal brain slices (350 µm) containing subthalamic 
nucleus and substantia nigra were cut using a microtome (Leica Microsystems, Nussloch, 
Germany) and transferred to a holding chamber containing artificial cerebrospinal fluid 
(ACSF) with 124 mM NaCl, 2.5 mM KCl, 1.3 mM MgSO4, 1.0 mM NaH2PO4, 2 mM 
CaCl2, 20 mM glucose, and 26 mM NaHCO3, equilibrated with 95% O2/5% CO2 and 
maintained at room temperature.  For all experiments, both choline replacement buffer 
and holding chamber ACSF buffer were supplemented with 5 µM glutathione, 500 µM 
pyruvate, and 250 µM kynurenic acid to increase slice viability.   
After one hour of recovery in the holding chamber, brain slices were then 
transferred to the slice recording chamber and maintained fully submerged with 
continuous perfusion of ACSF (2-3 ml/min). Neurons in the subthalamic nucleus (STN) 
or substantia nigra pars reticulata (SNr) were visualized with a 40x water immersion lens 
with Hoffman modulation contrast optics. Patch electrodes were pulled from borosilicate 
glass on the Narishige (East Meadow, NY) vertical patch pipette puller and filled with 
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internal solution: 125 mM potassium gluconate, 4 mM NaCl, 6 mM NaH2PO4, 1 mM 
CaCl2, 2 mM MgSO4, 10 mM BAPTA-tetrapotassium salt, 10 mM HEPES, 2 mM Mg-
ATP, and 0.3 mM Na2-GTP; pH adjusted to 7.3 with 1 N KOH. Electrode resistance was 
3 to 7 M . All whole-cell patch-clamp recordings were performed using a MultiClamp 
700B amplifier (Molecular Devices, Sunnyvale, CA). Data were digitized with DigiData 
1322A (Molecular Devices), filtered (2 kHz), and acquired by the pClamp 9.2 program 
(Molecular Devices). After formation of a whole-cell configuration, the recorded neurons 
were current-clamped to -60 mV. Membrane potentials of STN or SNr neurons were 
recorded. All compounds were applied by adding into perfusion solution. Data were 
analyzed using Clampfit 9.2 (Molecular Devices). All results are expressed as 
mean±SEM, statistical significance was determined using Student’s t test. 
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Results 
 
CDPPB displaces [3H]methoxyPEPy binding on mGluR5 competitively.  
We previously reported that CDPPB completely displaces binding of the allosteric 
site ligand [3H]methoxyPEPy to membranes from cells stably expressing mGluR5 
(Kinney et al., 2005). We now performed saturation binding experiments with increasing 
concentrations of [3H]methoxyPEPy in the presence or absence of two concentrations of 
CDPPB and data transformed using a Scatchard analysis to determine whether this is 
consistent with competitive interaction of CDPPB with the [3H]methoxyPEPy binding 
site (Limbird, 1996) (Figure 2-1).   Non-specific binding was defined as binding in the 
presence of 5 µM MPEP and subtracted from total binding. In the absence of CDPPB, 
Scatchard analysis of [3H]methoxyPEPy binding reveals a straight line (r2 = 0.77), 
demonstrating interaction at a single binding site. The X-intercept indicates a binding 
density (BBmax) of approximately 2300 fmol/mG-protein in this membrane preparation and 
the slope reveals an apparent KD value of 6.2 nM, consistent with previous results. 
Addition of CDPPB induced a shift in the slope of the regression line but no effect on the 
X-intercept, suggesting that CDPPB has no effect on the receptor density. However, the 
apparent affinity of [ H]methoxyPEPy was reduced by CDPPB, with K3 D values of 8.3 nM 
and 12 nM for 1 μM CDPPB and 2.5 μM CDPPB respectively. The maintenance of a 
linear Scatchard regression (r = 0.74 and r = 0.69 for 1 μM and 2.5 μM CDPPB, 
respectively) with change in apparent K
2 2 
D and no change in BmaxB  is consistent with the 
hypothesis that CDPPB competitively displaces [3H]methoxyPEPy binding at the MPEP 
binding site.  
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Figure 2-1: CDPPB reduces [3H]methoxyPEPy binding to mGluR5 in a competitive 
manner. Scatchard analysis showed that CDPPB dose-dependently decreases 
[3H]methoxyPEPy binding affinity but does not alter maximum binding. Saturation 
binding on membranes from mGluR5 stable HEK cell line was performed in the absence 
or presence of CDPPB. X-intercepts showed maximum binding under different binding 
conditions. In the absence of CDPPB, BBmax was 2312 ± 355 fmol/mg of protein, with 1 or 
2.5 µM CDPPB, BmaxB  was 2350 ± 366 or 2135 ± 251 fmol/mg of protein, respectively, 
showing no significant differences in BBmax [ H]methoxyPEPy (Student's t test). Linear 
regression lines were generated from four independent experiments in duplicate. Error 
bars represent S.E.M. 
3
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Potencies of CDPPB analogs at potentiating mGluR5 responses correlate 
significantly with their affinities at the [3H]methoxyPEPy binding site.  
 
The finding that CDPPB displaces [3H]methoxyPEPy binding in a manner that is 
consistent with competitively interaction with this allosteric MPEP binding site raises the 
possibility that binding to this site is necessary for allosteric potentiator activity. However, 
another allosteric potentiator of mGluR5, CPPHA, does not bind to this site (O’Brien et 
al., 2004). Also, the potency of CDPPB as the mGluR5 allosteric potentiator is more than 
one order of magnitude higher than its apparent affinity at the MPEP binding site (Kinney 
et al., 2004, de Paulis et al., 2006). Thus, it is possible that CDPPB-induced potentiation 
of mGluR5 responses is unrelated to its interaction with the allosteric MPEP site. To 
address this, we synthesized a series of structural analogs of CDPPB to determine 
whether affinities of these compounds at the MPEP site are closely related to their 
potencies at potentiating mGluR5 (de Paulis et al., 2006). We selected ten of these 
compounds based on their close structural similarity to CDPPB, and with no changes to 
the diphenylpyrazole portion of the molecule (de Paulis et al., 2006). Concentration-
response analysis revealed that these compounds potentiate calcium mobilization 
responses to the mGluR5 agonist glutamate with potencies that range from 9 nM to 228 
nM as mGluR5 allosteric potentiators (Figure 2-2; Table 2-1). One compound, VU-137, 
was inactive as an mGluR5 potentiator. VU-29 was the most potent allosteric potentiator 
in this group with potency of 9 nM. None of these ten compounds showed significant 
activities as allosteric potentiators of mGluR1 concentrations up to 10 µM (Hemstapat et 
al., 2006). Radioligand binding studies revealed that 9 of the 10 CDPPB analogs displace 
[3H]methoxyPEPy in a concentration-dependent manner (data not shown).  Interestingly, 
the one compound that was inactive at displacing [3H]methoxyPEPy binding, VU-137, 
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was also inactive at potentiating mGluR5-mediated calcium mobilization responses 
(Figure 2-2). Similar to CDPPB, the potencies of multiple compounds in the CDPPB 
series at potentiating glutamate-mediated functional responses were higher than their 
affinities at displacing [3H]methoxyPEPy from its binding site (Table 1). However, 
regression analysis of the affinities at the MPEP site versus allosteric potentiator 
potencies revealed that there is a close correlation between binding affinities to this site 
and potentiator activity (Figure 2-3) (r = 0.89; p<0.001). This, together with the finding 
that VU-137 is inactive in either binding to the MPEP site or as an allosteric potentiator is 
consistent with the hypothesis that binding to this site is required for allosteric potentiator 
activity. Having identified VU-29 as a highly potent allosteric potentiator of mGluR5, we 
used this compound in further studies aimed at characterizing this response.   
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 Figure 2-2: CDPPB analogs have a range of potencies on secondary cultured rat 
astrocytes as mGluR5 allosteric potentiators. A, chemical structures of selected 
CDPPB analogs. B, intracellular calcium mobilization responses were measured in 
response to an EC20 concentration of glutamate in the absence or presence of different 
concentrations of CDPPB analogs. The EC20 concentration for glutamate was 
determined each day and ranged from approximately 270 to 320 nM. CDPPB and its 
analogs induced a concentration-dependent increase in the response to this EC20 
glutamate concentration. Data were normalized to the maximum response of each 
reaction determined by 10 µM glutamate. Concentration-response curves were 
generated from three independent experiments each performed in duplicate. Error bars 
represent S.E.M. 
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Table 2-1: Affinities of CDPPB analogs at the MPEP binding site and their potencies as 
mGluR5 PAMs. Affinities (Ki) were obtained from [3H]methoxyPEPy competition 
binding using membrane prep from the rmGluR5 stable cell line and potencies from 
glutamate-induced calcium release in cultured rat cortical astrocytes. Data are average ± 
S.E.M. from three or four independent experiments in duplicate. 
 
 
10.6 ± 394.9 ± 41VU-36 
16.9 ± 6.2287 ± 64VU-35 
9.0 ± 1.5244 ± 90VU-29 
46.5 ± 18.6920 ± 362VU-28 
26.2 ± 9.4606 ± 263VU-24 
41.4 ± 17.8604 ± 180VU-23 
228 ± 391,310 ± 162VU-22 
87.1 ± 22.21,400 ± 428 VU-21 
175 ± 46.4 3,800 ± 854 VU-20 
44.8 ± 20.81,340 ± 233CDPPB 
EC50 (nM)Ki (nM) 
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Figure 2-3: The potencies of CDPPB analogs as mGluR5 PAMs significantly correlate 
with their affinities at the [3H]methoxyPEPy binding site (r = 0.89, p < 0.001). 
Membranes were prepared from rmGluR5 stable Chinese hamster ovary cell line; 2 
nM [3H]methoxyPEPy was used for the competition binding assay, and 5 µM MPEP 
was used to determine nonspecific binding. Data were obtained from three or four 
separate experiments each performed in duplicate. 
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5MPEP antagonizes VU-29 mediated potentiation of mGluR5 response.  
We recently reported the discovery and characterization of a novel compound that 
is a positional isomer of MPEP, 5MPEP, that acts as a neutral ligand at the allosteric 
MPEP site and blocks responses of both allosteric antagonists and potentiators 
(Rodriguez et al., 2005).  Consistent with previous results, 10 μM 5MPEP completely 
blocked the potentiation of the calcium mobilization response to glutamate by 60 nM 
VU-29 (p<0.001; Figure 2-4A, 2-4B).  Concentration response analysis revealed that 
blockade of the response to VU-29 by 5MPEP is concentration-dependent with an IC50 
value of 5MPEP of 710 ± 170 nM (Figure 2-4C), which is consistent with the IC50 of 
5MPEP at blocking the antagonist effect of MPEP (Rodriguez et al., 2005). 
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Figure 2-4: 5MPEP is a neutral antagonist of VU-29. A, calcium fluorescence responses 
of cortical astrocytes to an EC20 concentration of glutamate added in the absence and 
presence of VU-29 and, in some cases, the neutral allosteric site ligand 5-MPEP. 
Glutamate was added (arrow) 5 min after the addition of 5MPEP and/or VU-29. B, mean 
(± S.E.M.) calcium fluorescence responses for each condition. 5MPEP (10 µM) did not 
alter the EC20 glutamate response. VU-29 enhanced the EC20 glutamate response 
approximately 3-fold (Student's t test, one tail, p < 0.001). 10 µM 5MPEP completely 
blocked the enhancement by 60 nM VU-29 to the baseline (Student's t test with VU-29 
potentiated response, one tail, p < 0.001). C, concentration-response relationship for 
inhibition of the response to VU-29 by 5MPEP. The response to 60 nM VU-29 plus and 
EC20 concentration of glutamate in the absence of 5MPEP is shown on the left. 5MPEP 
dose-dependently antagonized VU-29-induced potentiation to a level similar to that of an 
EC20 concentration of glutamate in the absence of VU-29 (shown at right). 5MPEP, 10 
µM; VU-29, 60 nM; EC20 glutamate, approximately 300 nM. Data were obtained from 
three or four separate experiments each performed in duplicate. 
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VU-29 is an agonist of N-terminal truncated mGluR5.  
If the allosteric potentiator of VU-29 and related compounds is due to actions in 
the 7TM spanning domain, where the allosteric MPEP binding site resides, it is possible 
that this compound could retain activity at a truncated mutant of mGluR5 in which the N-
terminal extracellular domain, including the glutamate binding domain, is missing. We 
have recently reported that MPEP and other allosteric modulators of mGluR5 can retain 
their activity in cells expressing this truncated form of the receptor (Goudet et al., 2004). 
However, with the glutamate binding site absent, this activity does not depend on the 
presence of glutamate and these ligands behave in a manner similar to orthosteric ligands 
at family A GPCRs. Consistent with our previous studies, in HEK cells transiently 
expressed N-terminal truncated mutant of mGluR5 MPEP behaved as an inverse agonist 
and inhibited baseline accumulation of inositol phosphates, a measure of coupling of 
mGluR5 to PI hydrolysis (Goudet et al., 2004) (Figure 2-5A). Consistent with its activity 
as a neutral ligand at the MPEP site, 5MPEP did not behave as an inverse agonist of the 
truncated receptor and also did not activate the truncated mutant (Figure 2-5A). 
Interestingly, VU-29, behaved as an agonist in this system and directly activated PI 
hydrolysis in a concentration-dependent manner in cells expressing the N-terminal 
truncated form of mGluR5 (Figure 2-5A). The agonist effect of VU-29 was inhibited by 
5MPEP (Figure 2-5B), which is consistent with the hypothesis that activation of PI 
hydrolysis in the cells is mediated by actions of VU-29 on the 7TM binding domain of 
mGluR5.   
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Figure 2-5: VU-29 is an agonist of N-terminal truncated mGluR5. A, VU-29 directly 
activated N-terminal truncated mGluR5. MPEP was an inverse agonist and 5MPEP 
did not activate or antagonize the truncated mutant. B, 5MPEP antagonized VU-29-
induced IP accumulation through truncated mGluR5. Error bars represent S.E.M. 
(This figure was contributed by Dr. Cyril Goudet) 
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Mutation that eliminates binding of allosteric antagonists to the MPEP binding also 
reduces the potentiation of mGluR5 by VU-29.  
 
Mutation of alanine at the 809 position of mGluR5 to valine mGluR5 (A809V) 
reduces binding of MPEP to mGluR5 and severely reduces the potency of MPEP as an 
mGluR5 allosteric antagonist (Pagano et al., 2000; Malherbe et al., 2003). In contrast, 
mutation of a neighboring amino acid, M801T, which is also in the 7TM domain, has 
little effect on the affinity and function of MPEP (Pagano et al., 2000; Malherbe et al., 
2003). If the allosteric potentiator activity of CDPPB and VU-29 require interaction with 
the allosteric MPEP site, a mutation that reduces binding of ligands to the MPEP site 
should also reduce activity of these compounds as allosteric potentiators, whereas 
mutation of this neighboring amino acid should not. Consistent with the previous report, 
the potency of MPEP on mGluR5 (A809V) was about 10 fold lower than its potency on 
the wild type receptor, whereas the potency of MPEP on mGluR5 (M801T) remained 
intact (Pagano et al., 2000 and data not show). Consistent with the hypothesis that 
allosteric potentiator activity of these compounds requires binding to the MPEP site, both 
CDPPB and VU-29 were inactive as allosteric potentiators at mGluR5 (A809V), whereas 
both compounds retained activity at mGluR5 (M801T). Thus, as demonstrated in stable 
mGluR5-expressing cell lines and astrocytes, CDPPB (1 μM) and VU-29 (200 nM), 
induced parallel leftward shifts of the glutamate concentration response curves in cells 
transiently transfected with wildtype mGluR5 (Figure 2-6A) or with mGluR5 (M801T) 
(Figure 2-6B). In contrast, neither compound induced a significant shift in the glutamate 
concentration response curve of mGluR5 (A809V) (Figure 2-6C). 
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 Figure 2-6: Single point mutation that eliminates radiolabeled MPEP binding also 
eliminates CDPPB- or VU-29-induced potentiation of mGluR5-mediated calcium 
mobilization in transiently transfected HEK293A cells. A, CDPPB analogs shifted 
glutamate concentration-response curves of wild-type rmGluR5 2.8 ± 0.6-fold (CDPPB, 
1 µM) and 2.5 ± 0.5-fold (VU-29, 200 nM) to the left, respectively. B, CDPPB analogs 
shifted glutamate concentration-response curves of rmGluR5 (M801T) 3.16 ± 0.91-fold 
(CDPPB, 1 µM) and 3.55 ± 0.54-fold (VU-29, 200 nM) to the left. C, CDPPB (1 µM) 
and VU-29 (200 nM) did not shift the glutamate concentration-response curves of 
rmGluR5 (A809V). Concentration-response curves were generated from three or four 
independent experiments performed in duplicate. Error bars represent S.E.M. 
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VU-29 is selective for mGluR5 relative to other mGluR subtypes.  
Discovery of VU-29 as an allosteric potentiator of mGluR5 with low nanomolar 
potency provides one of the most potent allosteric potentiators of mGluR5 to date. The 
potency and solubility properties of this compound make VU-29 well suited to use in 
functional studies aimed at determining the physiological effects of allosteric potentiators 
of mGluR5. However, before using this compound to probe mGluR5 function, it is 
important to determine the selectivity of VU-29 for mGluR5 relative to other mGluR 
subtypes. We previously reported that this compound is without allosteric potentiator 
activity on mGluR1 (Hemstapat et al., 2006). We now determined the effects of this 
compound on mGluR2 and mGluR4 as representative members of the other major 
subgroups of mGluRs (group II and group III respectively). For measurement of 
responses to activation of mGluR2 and mGluR4, these receptors were co-transfected with 
chimeric G-protein-Gqi5 which allows coupling of these receptors to activation of 
phospholipase C (PLC) and calcium mobilization. A concentration of VU-29 (1 µM) that 
is capable of inducing maximal potentiation of mGluR5-mediated responses did not 
potentiate responses to activation of mGluR2 (Figure 2-7A) or mGluR4 (Figure 2-7B).  
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 Figure 2-7: VU-29 does not potentiate mGluR1-, -2-, or -4-mediated responses. A 
concentration of VU-29 that maximally potentiates mGluR5 responses (0.5 µM) neither 
potentiates nor antagonizes mGluR1- (A), mGluR2- (B), and mGluR4-mediated (C) 
responses in transiently transfected HEK 293A cells as measured using the calcium 
mobilization assay. Concentration-response curves were generated from three to four 
independent experiments performed in duplicate. Error bars represent S.E.M. ((This 
figure was contributed by Dr. Kamondanai Hemstapat) 
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CDPPB and its analogs potentiate excitatory effects of DHPG on neurons in the 
STN neurons but not the SNr. 
Previous studies reveal that the metabotropic receptor subtypes mGluR5 and 
mGluR1 are postsynaptically localized on neurons in the STN and SNr. Activation of 
mGluR5 by DHPG elicits depolarization in STN neurons, which can be blocked by the 
mGluR5-selective antagonist MPEP (Awad et al., 2000), whereas, mGluR1 plays a 
predominant role in regulating activity of neurons in the SNr (Marino et al., 2001). 
However, both of these neuronal populations express both mGluR1 and mGluR5 and 
previous studies suggest that each of these receptor subtypes can contribute to 
depolarization of either neuronal population under certain pathological conditions such as 
dopamine depletion (Marino et al., 2002a). Thus, while it is possible that selective 
mGluR5 potentiators will selectively potentiate responses that are normally mediated by 
the respective mGluR subtype, it is also possible that these compounds could recruit 
mGluR5 activity in neurons in which this receptor is present but does not normally 
contribute to neuronal depolarization. Whole-cell recordings were performed in STN and 
SNr neurons in rat midbrain slices to determine whether CDPPB and its analogs 
selectively potentiate mGluR5-mediated responses in STN neurons while exerting no 
effect on DHPG-induced depolarization of neurons in the SNr. Consistent with previous 
reports, bath application of 10 µM DHPG induced a depolarization in STN neurons (6.9 
± 1.2 mV, n=6 cells, Figure 2-8), and CDPPB (10 µM) enhanced the DHPG-induced 
responses (13.4 ± 1.5 mV, n=8 cells, Figure 2-8). The new higher potency CDPPB analog 
VU-29 (1 µM) had no effect on the membrane potential of STN neurons during 10 to 15 
min application period. However, in the presence of 1 µM VU-29, DHPG (10 µM) 
elicited stronger depolarization in STN neurons (13.2 ± 1.3 mV, n=8 cells, Figure 2-8) 
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when compared with the effect of DHPG (10 µM) alone. In addition, VU-23, the 3-nitro 
analog of CDPPB, potentiated DHPG-induced responses in STN neurons at a 
concentration of 10 µM (12.4 ± 2.1 mV, n=7 cells). In contrast to CDPPB and its analogs, 
the mGluR1-selective allosteric potentiator Ro 67-7476 (Knoflach et al, 2001) (3 µM) did 
not potentiate DHPG-induced (10 µM) depolarization in STN neurons (7.64 ± 1.23 mV, 
n=9 cells, Figure 2-8), suggesting that the mGluR1 potentiator does not recruit mGluR1-
mediated depolarization of these cells and the mGluR5 mediated response in STN 
neurons is specifically enhanced by the mGluR5 allosteric modulators. 
We next determined the effect of CDPPB analogs on DHPG-induced depolarization of 
SNr neurons, a response that is normally mediated exclusively by mGluR1 (Marino et al., 
2001). Consistent with previous reports (Marino et al, 2001), DHPG (3µM) induced a 
depolarization in SNr neurons (5.45 ± 0.93 mV, n=6, Figure 2-9) and the DHPG-induced 
response was blocked by the mGluR1 selective antagonist CPCCOEt (7-
hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester) (data not show). In 
contrast to its effects in STN neurons, VU-29 (1 µM) did not potentiate DHPG-induced 
(3 µM) depolarization in SNr neurons (7.7 ± 1.9 mV, n=11 cells, Figure 2-9). However, 
the mGluR1 potentiator Ro 67-7476 (3 µM) enhanced DHPG-induced (3 µM) 
depolarization in SNr neurons (13.3 ± 2.7 mV, n=7 cells, Figure 2-9). Taken together, 
these data indicate that mGluR5 allosteric modulator CDPPB and its analogs act as potent 
and selective positive allosteric modulators of native mGluR5 in STN neurons, whereas 
mGluR1 allosetric modulator Ro 67-7476 selectively potentiates mGluR1-mediated 
responses in SNr neurons. 
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 Figure 2-8: CDPPB and its analogs potentiate DHPG-induced depolarization in STN 
neurons. A, representative traces show depolarization elicited by application of DHPG 
(10 µM) alone, DHPG plus VU-29 (1 µM), and DHPG plus Ro 67-7476 (3 µM) in STN 
neurons. B, bar graph (mean ± S.E.M.) illustrates depolarization values elicited by DHPG 
(n = 6 cells), DHPG plus CDPPB (n = 8 cells), DHPG plus VU-29 (n = 8 cells), DHPG 
plus VU-23 (n = 7 cells), and DHPG in the presence of plus Ro 67-7476 (n = 9 cells) in 
STN neurons. *, p < 0.01, Student's t test. (This figure was contributed by Dr. Yi Nong) 
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 Figure 2-9: CDPPB analogs do not potentiate DHPG-induced depolarization in SNr 
neurons. A, representative traces showing depolarization of SNr neurons by application 
of DHPG (3 µM), DHPG (3 µM) plus Ro 67-7476 (3 µM), and DHPG plus VU-29 (1 µM) 
in SNr neurons. B, bar graph (mean ± S.E.M.) illustrates depolarization of SNr neurons 
by DHPG (n = 6 cells), DHPG plus Ro 67-7476 (n = 7 cells), and DHPG in the presence 
of VU-29 (n = 11 cells). *, p < 0.01, Student's t test. (This figure was contributed by Dr. 
Yi Nong)
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Discussion 
 
 
Three families of mGluR5 selective allosteric potentiators have now been 
reported from distinct structural groups. These are represented by DFB, CPPHA and 
CDPPB (O’Brien, et al., 2003; O’Brien et al., 2004; Kinney et al., 2005). DFB and 
CDPPB inhibit binding of ligands to the site labeled by allosteric antagonists, such as 
[3H]methoxyPEPy and [3H]MPEP. However, CPPHA does not displace binding to this 
site, suggesting that allosteric potentiator activity does not always require interaction with 
the MPEP site. Furthermore, we recently reported that three structurally distinct families 
of allosteric potentiators of mGluR1 do not share a common binding site with allosteric 
antagonists at this receptor (Hemstapat et al., 2006). Finally, the potency of CDPPB at 
displacing antagonist binding to the MPEP site is considerably lower than the potency of 
this compound as an mGluR5 allosteric potentiator. Together, these data raise the 
question as to whether displacement of [3H]methoxyPEPy binding is important for the 
allosteric potentiator activity of this compound. The present results provide strong 
evidence that CDPPB inhibits allosteric antagonist binding to the MPEP site in a manner 
consistent with a competitive interaction and that interaction with this site is important 
for allosteric potentiator activity. Scatchard analysis reveals the competitive nature of 
CDPPB interactions with this site. This is consistent with the hypothesis that CDPPB is 
not binding to a separate site to allosterically reduce [3H]methoxyPEPy binding (Limbird, 
1996). Further, our results show that there is a close correlation between the apparent 
affinities of several structural CDPPB analogs at the MPEP site and their activities as 
allosteric potentiators of mGluR5, suggesting that these two activities are interrelated. In 
addition, point mutations that reduce binding of MPEP and related compounds to the 
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allosteric mGluR5 antagonist site also reduce the ability of CDPPB and its analogs to 
potentiate mGluR5 responses. Taken together, these data suggest that CDPPB and its 
analogs share a common or partly overlapping binding site with mGluR5 allosteric 
antagonists and that binding to this site is important for both the activity of CDPPB and 
related allosteric potentiators and previously known allosteric mGluR5 antagonists.    
Given the finding that interaction with the MPEP site is critical for allosteric 
potentiator activity, it is interesting that allosteric potentiators of mGluR5 consistently 
have higher potencies at potentiating responses to glutamate than their apparent affinities 
at the MPEP binding site. This is the case in multiple systems, including astroctyes 
studied here as well as cell lines stably expressing mGluR5 (Kinney et al., 2005) and 
cells transiently transfected with mGluR5 (unpublished findings). Thus, full allosteric 
potentiator activity can be achieved with concentrations of allosteric potentiators that 
displace a relatively small fraction of ligand binding to the MPEP sites. Importantly, 
CDPPB can also directly activate mGluR5 in some systems.  For instance, unlike the 
situation in astrocytes, we previously reported that higher concentrations of this 
compound can directly activate mGluR5, as measured by calcium fluorescence, in the 
absence of glutamate in cell lines stably expressing mGluR5 (Kinney et al., 2005).  
Interestingly, the EC50 for direct activation of mGluR5 by CDPPB in the absence of 
glutamate is in the low µM range, which is closer to the CDPPB apparent Ki value at 
mGluR5. We have observed a similar activation of mGluR5-mediated calcium responses 
by CDPPB and its analogs in another stable cell line with consistently lower potencies 
relative to potentiation of responses to glutamate in the same cell line (unpublished 
findings). Similarly, we report here that VU-29 directly activates a truncated mutant form 
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of mGluR5 in which the extracellular glutamate binding domain has been deleted. The 
EC50 value of VU-29 at activating the truncated receptor is similar to its apparent Ki 
value at the allosteric MPEP site. The simplest explanation for the difference between 
modulator potency when tested against glutamate and modulator affinity for the free 
receptor is that the former parameter is influenced by the positively cooperative 
interaction between the modulator and glutamate when both occupy the receptor 
simultaneously.  The greater the positive cooperativity, the greater the degree of left-shift 
in modulator potency.  In contrast, when the modulator is tested on its own as an agonist, 
the potency derived from this latter type experiment will simply reflect the affinity of the 
modulator for the free receptor and the strength of stimulus-response coupling.  Since 
CDPPB is a very weak agonist in its own right, coupling efficiency is very low and hence 
the potency of CDPPB as an agonist should be close to its binding affinity. 
Current studies indicate that there are multiple allosteric potentiation sites on 
mGluR5. Among the current 3 families of mGluR5 allosteric potentiators, DFB has been 
shown to interact at the MPEP binding site as evidenced by competitive 
[3H]methoxyPEPy binding and by point mutations that eliminate [3H]MPEP binding and 
reduce DFB potentiation (O’Brien, et al., 2003; Chen et al., 2004). Here, we have 
confirmed that CDPPB series of allosteric potentiators also acts through interaction to the 
same site as MPEP.  Giving the fact that CPPHA does not inhibit [3H]methoxyPEPy 
binding to its site up to 100 µM (O’Brien et al., 2004), it is clear that CPPHA does not 
interact with MPEP binding site. Thus, we propose that there are multiple allosteric 
potentiatior sites on mGluR5. Allosteric potentiators that bind to different sites may 
regulate mGluR5 activity differentially. A recent study has shown that CPPHA and DFB 
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have different modulatory profiles on mGluR5-mediated ERK1/2 phosphorylation in 
secondary cultured rat cortical astrocytes (Zhang et al., 2005). Based on this, it is possible 
that allosteric modulators that potentiate activity of a single receptor by different 
mechanisms may have distinct physiological effects. The finding that CDPPB series of 
allosteric potentiators act through a shared binding site with MPEP does not necessarily 
imply that CDPPB analogs interact with identical amino acid residues as MPEP. It is 
more likely that they are interacting through binding to different amino acids in a largely 
overlapping pocket.  Several residues in TM3, 6 and 7 have been mapped out as crucial 
interaction sites for MPEP (Pagano et al., 2000; Malherbe et al., 2003). However, the 
exact amino acid residues that constitute the binding pockets for MPEP or CDPPB are 
not currently known. 
Interestingly, we have now identified ligands that interact with the MPEP site that 
have a range of activities from allosteric antagonists to allosteric potentiators, and include 
neutral ligands that interact with this allosteric site but have no intrinsic activity. This is 
in some ways analogous to the range of activities of ligands at orthosteric sites that 
includes agonists, inverse agonists, and neutral antagonists. However, it is interesting to 
note that compounds within a single chemical series that span this entire range of activity 
appear to be rare.  For instance, analysis of the effects of almost 50 analogs of CDPPB 
has not revealed any compounds in this series that act as allosteric antagonists or neutral 
ligands (DePaulis et al., 2006; Hemstapat et al., 2006). Similarly, many members of the 
CDPPB series can also act as allosteric potentiators of mGluR1, but none of these 
compounds have neutral or allosteric antagonist activity at mGluR1 (Hemstapat et al., 
2006). Furthermore, analysis of many analogs of MPEP has yielded many allosteric 
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antagonists and a small number of neutral ligands but no allosteric potentiators in the 
MPEP series. (Gasparini et al., 1999; Rodriguez et al., 2005; Alagille et al., 2005a; 2005b; 
Iso et al., 2006). This suggests clear differences in the structural requirements of different 
activities at allosteric sites on mGluRs. However, it is also important to note that the 
benzaldazine series of compounds, exemplified by 3,3'-Difluorobenzaldazine (DFB), also 
interacts with the MPEP site and includes closely related members that act as allosteric 
antagonists, allosteric potentiators, and neutral ligands (O’Brien et al., 2003). 
 Discovery of VU-29 as an allosteric potentiator of mGluR5 with nM potency 
provides a useful tool for studying the physiological impact of selective potentiation of 
this receptor subtype.  Importantly, VU-29 was found to be selective for mGluR5 relative 
to mGluRs 1, 2, and 4. In recent years, it has become clear that multiple neuronal 
populations express both mGluR1 and mGluR5 but that these receptors have distinct 
physiological effects. For instance, neurons in the STN express both of these mGluR 
subtypes but under normal conditions only mGluR5 participates in depolarization of STN 
neurons by the mGluR1/5 agonist DHPG.  However, under some conditions, activation of 
mGluR1 can substitute for mGluR5 and depolarize STN neurons in response to DHPG 
(Awad et al., 2000; Marino et al., 2001; 2002a). The opposite is true in SNr projections 
neurons. Only mGluR1 is involved in DHPG-induced depolarization under normal 
conditions but mGluR5 is also present and can induce calcium transients and can 
depolarize these cells under some conditions (Marino et al., 2001; 2002a).  Theoretically, 
it is possible that VU-29 and other allosteric potentiators could selectively potentiate 
responses to DHPG that are normally mediated by mGluR5.  However, it is also possible 
that by potentiating mGluR5 activity, these compounds could also lead to coupling of 
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mGluR5- to responses in which it does not normally participate in cells that express this 
receptor. The finding that VU-29 and related mGluR5 potentiators enhanced DHPG-
induced depolarization of STN neurons but not of SNr neurons and that the mGluR1 
potentiator Ro 67-7476 had the opposite effects suggests that, in these cells, these 
compounds potentiate the normal response to mGluR5 or mGluR1 activation but 
maintain the normal physiological roles of these receptor subtypes. This is of critical 
importance in considering the physiological impact of these compounds in intact systems.  
In future studies these compounds will provide excellent tools for understanding the 
impact of selective potentiation of mGluR1 and mGluR5-mediated responses in a range 
of neuronal populations and circuits. 
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CHAPTER III 
 
CPPHA ACTS THROUGH A NOVEL SITE AS A POSITIVE ALLOSTERIC 
MODULATOR OF GROUP 1 METABOTROPIC GLUTAMATE RECEPTORS. 
 
Introduction 
Group I mGluRs are distributed widely in multiple brain regions.  Positive 
allosteric modulators (PAMs) of group 1 mGluRs have recently emerged as useful tools 
to study their physiological roles and provide a promising approach for developing novel 
therapeutic agents for treatment of psychiatric and cognitive disorders (Anwyl 1999; 
Marino et al 2002; O’Brien, et al., 2003; O’Brien et al., 2004; Campbell et al., 2004; 
Moghaddam, 2004; Kinney et al., 2005;). 
                  Three distinct families of mGluR5 PAMs have been developed including DFB, 
CPPHA and CDPPB (O’Brien, et al., 2003; 2004; Kinney et al., 2005). The mGluR5 
PAMs do not activate the receptor directly but potentiate its response to glutamate.  
Unlike allosteric modulators of other GPCRs, mGluR5 PAMs do not affect binding of 
ligands to the orthosteric glutamate binding site (Christopolous and Kenakin, 2002; 
O’Brien, et al., 2003; O’Brien et al., 2004; Kinney et al., 2005). DFB and CDPPB 
displace binding of a radioligand to a well characterized binding site for mGluR5 
negative allosteric modulators (NAMs), such as MPEP.   Furthermore, we have provided 
evidence that the CDPPB family of PAMs (including VU-29) exert their potentiation 
effects by actions at this site (Chen et al., 2007). Interestingly, a third PAM, CPPHA, 
does not bind to the MPEP site at concentrations several magnitudes higher than its PAM 
potency (O’Brien et al., 2004), suggesting that CPPHA acts by a different mechanism 
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than do CDPPB, VU-29, and DFB. However, PAMs and orthosteric agonists activate 
mGluR5 in a cooperative manner so that relatively low occupancy at the MPEP site can 
induce robust potentiation of mGluR5 responses (Chen et al., 2007; DePaulis et al., 2006). 
Thus, CPPHA could potentiate mGluR5 by actions at this site but have low affinity and 
high cooperativity so that low binding is not detectable at concentrations that have been 
used in radioligand binding studies.  We now report a series of studies that suggest that 
CPPHA potentiates responses to activation of both mGluR5 and mGluR1 by actions at a 
site that is clearly distinct from the previously identified allosteric sites on either of these 
receptor subtypes. These data suggest that multiple distinct allosteric sites exist on 
mGluRs that can serve as targets for PAMs to induce qualitatively similar effects on 
receptor function.   
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Materials and Methods 
 
Mutagenesis and transient transfection. 
HEK 293A cells (Invitrogen, Carlsbad, CA) were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Invitrogen) containing 10% fetal bovine serum (FBS, 
Invitrogen), 1mM L-glutamine (Invitrogen) and 1× Antibiotic-Antimycotic (Invitrogen).  
Cells were collected and plated in clear-bottom-96-well plates (Costar, Corning Life 
Sciences) pretreated with poly-D-lysine (Sigma) in normal growth medium with a density 
of 40,000 cells per well overnight before transfection. Cells were transiently transfected 
with wild type and mutant forms of rat mGluR5a/mGluR1 cDNA using the pRK5 vector 
(BD Biosciences Clontech, Palo Alto, CA).  Point mutations were generated using the 
Quick Change II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA). 
Construction of the N-terminal truncated mutant of mGluR5 was performed as reported 
by Goudet et al. (2004). All mutations were verified by sequencing. The transfection 
plasmid was prepared using Sigma Mini Prep kit (Sigma-Aldrich, St Louis, MO). Cells 
were transfected with lipofectamine (Invitrogen) for 6 h according to the manufacturer’s 
instructions (80ng DNA and 0.2 µl lipofectamine per well) before switching to normal 
growth medium. Rat GLAST pCDNA3.1 (20 ng per well) was co-expressed with 
mGluR5 pRK5 to reduce extracellular glutamate concentration for the test of VU-29. 
Glutamate/glutamine free medium (glutamine free DMEM plus 10% dialyzed fetal 
bovine serum, Invitrogen) was applied to substitute growth medium at least 4 hours 
before performing functional assays. Cell culture, transfection and starving were 
performed at 37°C in an atmosphere of 95% air plus 5% carbon dioxide. Transfected cells 
 73
were tested about 48 h after transfection. Rat mGluR2 and human mGluR4 were co-
expressed with Gqi5 which enables coupling to the calcium mobilization as reported by 
Gallici et al., (2006). 
 
Secondary rat astrocytes culture. 
Secondary rat cortical astrocytes were prepared as described (Peavy et al., 2001; 
Zhang et al., 2005; Chen et al., 2007). Detailed protocol has been described in Chapter II. 
 
Calcium fluorescence measurement. 
Cells were loaded with calcium-sensitive dye according to the manufacturer’s 
instructions (Calcium 3 kit; Molecular Devices Corp., Sunnyvale, CA) after incubated in 
glutamate/glutamine free medium (DMEM and 10% dialyzed fetal bovine serum) for five 
hours.  1 ml compound A from Calcium 3 kit was dissolved in 20 ml of 1× Hanks’ 
balanced salt solution (HBSS, Invitrogen/Gibco) containing 2.5 mM probenicid (Sigma), 
adjusted to pH 7.4. Cells were loaded for 50 min at 37°C with 5% carbon dioxide.  Dye 
was then carefully removed and cells were washed with HBSS containing probenicid.  
Cells were maintained in the same buffer at room temperature for the following assay.  
For calcium fluorescence measurement of rat cortical astrocytes, allosteric modulators 
were added 5 min before the addition of agonist manually. For transient transfected cells, 
VU-29 was added 1 min before the addition of agonist using Flexstation II (Molecular 
Devices Corp.) at a speed of 52 µl/s.  CPPHA was added 5 min before agonist. Calcium 
flux was measured at 25°C. All the peaks of the calcium response were normalized to the 
maximum response to a saturated dose of glutamate (10 µM).  The submaximal 
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concentration (EC20) of glutamate was determined for every separate experiment, 
allowing for a response varying from 10% to 30% of the maximum peak. 
 
Inositol Phosphate measurement. 
Inositol phosphate (IP) accumulation experiments were performed in 96-well 
microplates as already described by Goudet et al. (2004). Briefly, after transfection of the 
truncated mGluR5 receptor, HEK293 cells were incubated overnight with 3H-myoinositol 
(16 Ci/mmole, Amersham, Buckinghamshire, UK). The following day, cell medium were 
washed and ambient glutamate degraded by incubation in presence of GPT. Cells were 
stimulated by the indicated compounds for 30 minutes then the medium was removed and 
cells incubated with cold 0.1 M formic acid which induced cell lysis. Then 3H-IP 
produced following receptor stimulation were recovered by ion exchange 
chromatography using a Dowex resin (Biorad). IP were then eluted by a highly 
concentrated formate solution (4 M), collected in a 96-wells sample plate and mixed with 
liquid scintillator (Perkin Elmer). The radioactivity remaining in the membranes is used 
to normalize the IP produced. Membranes were solubilized with a solution of NaCl (0.1 
M) containing 10% of Triton X100 (Sigma), collected and mixed with liquid scintillator 
in a 96-well sample plate. Radioactivity was counted using a Wallac 1450 Microbeta 
stintillation and luminescence counter (Perkin Elmer). Results are expressed as the ratio 
between IP and the total radioactivity corresponding to IP plus membrane. All points are 
realized in triplicate.   
 
 75
[3H]R214127 Radioligand Binding Assays. 
Membranes preparation from BHK cells stably expressing rat mGluR1a and [3H]1-(3,4-
dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-2-phenyl-1-ethanone ([3H]R214127) 
competition binding assay was performed following the protocol described in Hemstapat 
et al., (2006).   Compounds were dissolved in DMSO as stocks kept in -20°C. The final 
DMSO concentration was 0.12% in the assay. 
 
Compound preparation. 
Compounds were dissolved in dimethyl sulfoxide (DMSO, Sigma) and stored at -
80ºC.  Stock solutions were dissolved in 1× HBSS containing 0.1% BSA (Albumin 
Bovine Serum, Sigma) on the day of experiment.  Final DMSO concentration was 0.12% 
to 0.15% for all the assays.   
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Results 
 
5MPEP blocks responses to CPPHA and VU-29 with different potencies.   
We used secondary cultured rat cortical astrocytes for the functional assay of 
mGluR5 (calcium mobilization assay). As previously described, the calcium fluorescence 
response to a threshold (EC20) concentration of glutamate (about 300 nM) was 
potentiated by 3 µM CPPHA (Figure 3-1A; student’s t-test, P<0.01). The neutral MPEP 
site allosteric modulator, 5MPEP (10 µM) (Rodriguez et al., 2005) had no effect on the 
EC20 glutamate response, however it blocked potentiation of this response by 3 µM 
CPPHA (Figure 3-1A; student’s t-test, P<0.01) in a manner similar to that previously 
shown for VU-29 (Chen et al., 2007).   Comparable sub-maximal concentrations of 
CPPHA and VU-29 were chosen (3 µM CPPHA and 60 nM VU-29) to generate 5MPEP 
concentration response curves.  The potency of 5MPEP at blocking the response to VU-
29 was 0.75 ± 0.2 µM whereas its potency at blocking the response to CPPHA was 2.27 
± 0.7µM on (Figure 3-1B).  These values were significantly different (student’s t-test, 
P<0.05).  Furthermore, the slope of the inhibition curve for blockade of the response to 
CPPHA appeared to be more shallow that for blockade of the response to VU-29. 
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Figure 3-1: 5MPEP have different potencies to block CPPHA and VU-29-induced 
potentiation of mGluR5-mediated intracellular calcium flux. A, 5MPEP blocked CPPHA-
induced potentiation of mGluR5-mediated intracellular calcium flux in the secondary 
cultured rat cortical astrocytes.  Pretreatment with 10 µM 5MPEP did not affect the 
response to glutamate (EC20, about 300nM).  3 µM CPPHA enhanced the response.  
5MPEP blocked the potentiation significantly.  Asterisk means P<0.01 (Student’s t test).  
B, 5MPEP blocks the effects of VU-29 and CPPHA in a dose dependent manner in the 
secondary cultured rat cortical astrocytes via calcium mobilization assay. Data was 
normalized to the maximum potentiation of each potentiator determined by 3µM of 
CPPHA or 60nM of VU-29 respectively showing as Control A. Control B shows the 
EC20 response of glutamate without any allosteric potentiator. The potency of 5MPEP on 
VU-29 was 0.745 ± 0.2 µM while it was 2.27 ± 0.72 µM for CPPHA (Student’s t test, P 
<0.05). Concentration-response curves were generated from three independent 
experiments, each performed in triplicate. Error bars represent S.E.M of 3 separate 
experiments. 
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5MPEP and MPEP have actions consistent with non-competitive blockade of the 
response to CPPHA.   
 
To determine whether 5MPEP blocks responses to VU-29 and CPPHA by similar 
mechanisms, we determined the effects of increasing concentrations of 5MPEP on the 
concentration response relationships of VU-29 and CPPHA-induced potentiation of 
mGluR5 responses (Figure 3-2). 5MPEP induced progressive parallel rightward shifts of 
the VU-29 CRC when added at concentrations up to 10 µM.  Thus, VU-29 was capable 
of overcoming inhibition by 5MPEP across this concentration range. Schild regression 
showed a linear line (r2=0.9921) with a slope of 0.9704.  The X-intercept was 100 nM, 
which fitted its Ki obtained from competition binding (Figure 3-2A; Rodriguez et al., 
2005).  This is consistent with a competitive mechanism of action of 5MPEP at blocking 
the VU-29 response.  In contrast, increasing concentrations of 5MPEP induced 
progressive decreases in the maximum potentiation of CPPHA (Figure 3-2B) suggesting 
that 5MPEP blocks the response to CPPHA by a non-competitive mechanism of action.   
We next performed similar experiments with MPEP.  Since MPEP is an mGluR5 
NAM instead of neutral modulator, this compound decreased the baseline response of the 
concentration response curves of both VU-29 and CPPHA.  Consistent with 5MPEP, 
MPEP induced dose dependent parallel rightward shifts in the VU-29 CRC but 
downward shifts in CRCs for CPPHA.  This is consistent with the effects of 5MPEP and 
the hypothesis that ligands acting at the MPEP site do not interact with CPPHA in a 
competitive manner (Figure 3-3A,B).    
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Figure 3-2: 5MPEP induces parallel rightward shifts in the VU-29 CRC but has non-
competitive actions on the response to CPPHA using calcium mobilization assay of rat 
astrocytes.  A, The concentration response curves of VU-29 were shifted to the right in a 
concentration-dependent manner by 5MPEP at concentrations up to 10 µM.   Schild 
regression showed a slope of 0.97 and X-intercept of 100nM.  B. 5MPEP blocks the CRC 
of CPPHA in a non-competitive manner.  Increasing concentrations of 5MPEP induced 
progressive decreases in the maximum response to CPPHA.  Data were obtained from 4 
separate experiments each performed in triplicate. Error bars represent S.E.M. 
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Figure 3-3: MPEP differentially shifts the concentration responses curves of VU-29 and 
CPPHA using the calcium mobilization assay of cultured rat cortical astrocytes. A, MPEP 
induced a parallel rightward shift in the CRC of VU-29 with no decrease of its maximum 
potentiation, suggesting competitive blockade. B, MPEP decreased the maximum effect 
of CPPHA, suggesting a non-competitive inhibitory action.  Data were obtained from 3 
separate experiments each performed in triplicate. Error bars represent S.E.M. 
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CPPHA has PAM activity at both mGluR1 and mGluR5.  
We next evaluated the selectivity of CPPHA as a potentiator of mGluR5 relative 
to mGluR1 and representative mGluR subtypes belonging to group II (mGluR2) and 
group III (mGluR4). CPPHA (10 µM) potentiated responses of both mGluR5 and 
mGluR1d to glutamate but had no effect on responses to mGluR2 (Figure 3-4C). 
Consistent with the original report, CPPHA showed slight antagonism on mGluR4 
mediated response (Figure 3-4D). CPPHA also potentiated rmGluR1a and 1b mediated 
calcium mobilization (data not shown). 
CRC analysis revealed that CPPHA had a potency of 239 ± 27 nM on rmGluR5 
and a potency of 3,460 ± 517 nM on rmGluR1d (Figure 3-5A,B).  Thus, while somewhat 
selective for mGluR5, CPPHA has clear effects at both group I mGluR subtypes.  This 10 
fold selectivity likely accounts for the failure to see an effect of a single lower 
concentration of CPPHA on mGluR1 in previous studies (O’Brien et al., 2004). 
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Figure 3-4: Selectivity of CPPHA for different mGluR subtypes in HEK 293 cells.  A and 
B, 10 µM CPPHA shifted the glutamate CRC for mGluR5 and mGluR1.  C, 3 or 10 µM 
rmGluR1d
-9 -8 -7 -6 -5 -4
0
20
40
60
80
100 CPPHA 10μM
Buffer
Log[Glu]
%
M
ax
 G
lu
 R
es
po
ns
e
rmGluR5
-9 -8 -7 -6 -5
0
20
40
60
80
100
Buffer
CPPHA 10μM
Log[Glu]
%
M
ax
 G
lu
 R
es
po
ns
e
rmGluR2
-8 -7 -6 -5 -4
20
40
60
80
100
Buffer
CPPHA 10μM
CPPHA 3μM
Log[Glu]
%
M
ax
 G
lu
 R
es
po
ns
e
A B
-9 -8 -7 -6 -5 -4
0
20
40
60
80
100
CPPHA 10μM
Buffer
hmGluR4
Log[L-AP4]
%
M
ax
 L
-A
P
4
R
ep
on
se
C D
%
M
ax
 G
lu
 R
es
po
ns
e
%
M
ax
 G
lu
 R
es
po
ns
e
%
M
ax
 G
lu
 R
es
po
ns
e
%
M
ax
 L
-A
P
4
R
ep
on
se
CPPHA did not affect the CRC of mGluR2 significantly.  D, 10 µM CPPHA slightly 
antagonized the response of mGluR4.  Data were obtained from 3 separate experiments 
each performed in triplicate. Error bars represent S.E.M. 
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 Figure 3-5: The potencies of CPPHA on mGluR1 and mGluR5 are slightly different. We 
pre-incubated transiently transfected HEK cells with multiple concentrations of CPPHA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
for 5 minutes, before adding EC20 concentrations of glutamate to elicit calcium 
mobilization. CPPHA had a potency of 239 ± 27 nM on rmGluR5 (A) and a potency of 
3,455 ± 517 nM on rmGluR1d (B).  Data were obtained from 3 separate experiments 
performed in triplicate. Error bars represent S.E.M. 
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CPPHA acts in the 7TM domain of group I mGluRs at a site distinct from that of 
VU-29.  
 
The studies above suggest that CPPHA and VU-29 likely act at distinct sites.  
Since VU-29 and other previously identified allosteric modulators of mGluR5 act at a 
common site that is shared with MPEP, this raises the question of what domains of the 
receptor are most important for the action of CPPHA. The MPEP site and sites for other 
previously identified allosteric modulators of mGluRs are in the 7TM domain of the 
receptor. However, it is conceivable that an allosteric modulator could act in the 
extracellular or intracellular domains. The finding that CPPHA is an allosteric potentiator 
of mGluR1d suggests that CPPHA is unlikely to act in the intracellular C-terminal 
domain of the receptor. Thus, mGluR1d is a C-terminal truncated receptor that lacks the 
large intracellular C-terminal domain. We previously reported that other allosteric 
potentiators of mGluRs act as agonists of N-terminal truncation mutants that lack the 
large extracellular domain (Goudet et al., 2004; Chen et al., 2007).  If CPPHA has a 
similar action, this compound is unlikely to act at a site in the N-terminal domain.  Thus, 
we determined the effect of CPPHA on the previously described N-terminal truncation 
mutant of mGluR5. Interestingly, CPPHA induced a robust activation of the truncated 
mutant as assessed by measures of activation of PI hydrolysis. This was qualitatively 
similar to the effect of VU-29 (Figure 3-6). These data suggest that, like other allosteric 
modulators, CPPHA is likely to act in the heptahelical domain of mGluR5.   
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Figure 3-6: CPPHA and VU-29 directly activated N-terminal truncated mGluR5. IP 
productions were expressed as the ratio between IP and the total radioactivity. (This 
figure was contributed by Dr. Cyril Goudet)
 
 
 
 
 
 
 
 88
  
 
 
igure 3-7: Sequence alignments of mGluR1, 5 and 2 transmembrane domains.   Bold 
letters show the amino acids have been mutated. 
rmGluR5 …PIAAVVFACLGLLATLFVTVIFI… LCYIILAGICLGYLCTFCLIA… 
rmGluR1 …SIIAIAFSCLGILVTLFVTLIFV… YIILAGIFLGYVCPFTLIA…
rmGluR2 …AVGPVTIACLGALATLFVLGVFV… LCYILLGGVFLCYCMTFVFIA… 
 
 
                  TM3                  TM4 
 
 
rmGluR5 …IGIGLSPAMSYSALVTKTN… LVIAFILICIQLGIIVALFIM… 
rmGluR1 …LLVGLSSAMCYSALVTKTN… ASILISVQLTLVVTLIIM…
rmGluR2 …LGLGTAFSVCYSALLTKTN… VAICLALISGQLLIVAAWLVV…
        
 
                  TM5                     TM6 
 
 
rmGluR5 …LGVVTPLGYNGLLILSCTFYAF… YIAFTMYTTCIIWLAFVPIYFGS…
rmGluR1 …LGVVAPVGYNGLLIMSCTYYAF… YIAFTMYTTCIIWLAFVPIYFGS…
rmGluR2 …ASMLGSLAYNVLLIALCTLYAF… FIGFTMYTTCIIWLAFLPIFYVT…
 
 
                  TM7 
 
 
rmGluR5 …MCFSVSLSATVALGCMFVPKVYIILA…
rmGluR1 …TCFAVSLSVTVALGCMFTPKMYIIIA…
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We took advantage of the ability of CPPHA to potentiate responses at mGluR1 
and mGluR5 but not mGluR2 to guide selection of mutations that may provide insights 
into specific amino acids that may be required for CPPHA action. Thus, we aligned the 
7TM domain of these receptors and searched for residues that were identical between 
mGluR1 and mGluR5 but in which there was a different amino acid in mGluR2. We 
selected 20 amino acids in the transmembrane domain that were identical between 
mGluR1 and 5 but were divergent in mGluR2. Mutants of mGluR5 were constructed in 
which each of these 20 amino acids was singly mutated to the corresponding amino acids 
in mGluR2. Sequence homology and all the mutants studied are shown in Figure 3-7. All 
the mutated plasmids were tested for responses to 1 µM CPPHA in transiently transfected 
HEK cells using the calcium mobilization assay. Among all the mutants, only 
A582P/F585I/mGluR5 and F585I/mGluR5 in the first transmembrane domain eliminated 
the potentation of mGluR5 by 1 µM CPPHA (Figure 3-8B). CPPHA induced a 
significant potentiation of responses for all other mutants (data not shown) as well as 
wildtype receptor (Figure 3-8A). In contrast, the potentiation of 200 nM VU-29 remained 
for F585I/mGluR5 compared with wildtype (Figure 3-8A,B).   
Previously we reported potentiation of VU-29 was abolished by A809V, which 
also eliminated MPEP site binding (Chen et al., 2007; Pagano et al., 2000 and Malherbe 
et al., 2003).  As can be seen in figure 3-8C, A809V eliminates the effect of VU-29 
without affecting the potentiation by CPPHA. 
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Figure 3-8: Two different point mutations in mGluR5 eliminate CPPHA or VU-29-
induced potentiation respectively.  A,1 µM CPPHA and 200 nM VU-29 induced leftward 
shifts of the glutamate CRC for wildtype rmGluR5 in transiently transfected HEK293 
cells as measured by the calcium mobilization assay. B, single point mutation F585I 
completely abolished CPPHA potentiation without changing VU-29 potentiation. C, 
A809V eliminated the VU-29 potentiation but remained CPPHA potentiation intact. Data 
shown represent means ± S.E.M of 3 separate experiments, each performed in triplicate. 
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To further verify the impact of this mutation on CPPHA responses, we 
determined the effect of mutation of the homologous amino acid in mGluR1. In 
transiently transfected HEK cells, both 3 µM CPPHA and 200 nM Ro 67-7476 potentiate 
WT mGluR1-mediated calcium mobilization (Figure 3-9A).  However, F599I/mGluR1, 
the homologous mutation of F585I/mGluR5, eliminated the potentiation of mGluR1 
responses by CPPHA but not a previously characterized mGluR1 PAM, Ro 67-7476 
(Knoflach et al., 2001; Hemstapat et al., 2006) (Figure 3-9B).  Furthermore, another 
mutation, V757L/mGluR1 abolished the potentiation of mGluR1 by Ro 67-7476 as 
previously reported (Knoflach et al., 2001; Hemstapat et al., 2006) but did not abolish the 
potentiation of CPPHA (Figure 3-9C). 
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Figure 3-9: Two different point mutations in mGluR1 eliminate CPPHA or Ro 67-7476-
induced potentiation respectively. A, 3 µM CPPHA and 200 nM Ro 67-7476 potentiated 
the CRC of glutamate to the left for wildtype rmGluR1d in transiently transfected HEK 
cells via calcium mobilization assay. B, Single point mutation F599I completely 
abolished CPPHA potentiation without changing Ro 67-7476 potentiation. C, V757L 
eliminated the Ro 67-7476 potentiation but remained CPPHA potentiation intact. Data is 
shown as means ± S.E.M of 3 separate experiments. 
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CPPHA does not compete for binding of to the allosteric antagonist R214127 site on 
mGluR1.   
 
The allosteric mGluR1 antagonist radioligand [3H]R214127 binds to mGluR1 at a 
site that is thought to be homologous with the MPEP site on mGluR5 (Pagano et al., 2000; 
Lavreysen et al., 2003).  If CPPHA acts at a site that is conserved between mGluR1 and 
mGluR5 but is distinct from the MPEP and R214127 sites on these receptors, CPPHA 
should not compete for binding to the R214127 site.  Thus, we determined the effect of 
CPPHA on specific binding of 2.5 nM [3H]R214127 to mGluR1.   Binding of 
[3H]R214127 to membranes from cells expressing mGluR1 was reduced in a 
concentration dependent manner by cold R214127 with a IC50 of 3.4 nM (Figure 3-10).  
Under the same conditions, CPPHA did not affect the [3H]R214127 binding up to 32 µM 
(Figure 3-10). 
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Figure 3-10: CPPHA does not bind to the R214127 NAM site on mGluR1.  R214127 
induced a concentration-dependent decrease in binding to of 2.5 nM [3H]R214127 to a 
membrane preparation from an mGluR1 stable cell line with a IC50 of 3.4 nM.  CPPHA 
did not affect the binding at concentrations up to 32 µM.  Data are shown as means ± 
S.E.M of 3 separate experiments each performed in triplicate. 
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Discussion 
The data reported in the in this chapter provide strong support for the hypothesis 
that CPPHA acts at a novel allosteric site on mGluR5 and mGluR1 to potentiate 
activation of the receptor by orthosteric agonists. Our data suggest that the action of 
CPPHA is similar to actions of other known allosteric modulators in that it is due to 
actions in the 7TM domain but that the specific site differs from previously defined sites 
for allosteric potentiators or allosteric antagonists on these receptors. Most of the 
mGluR5 allosteric antagonists are derived from the same chemical scaffold and are 
believed to act on a shared site represented by the MPEP binding site (Varney et al., 1999; 
Gasparini et al., 1999).  There are three families of PAMs for mGluR5, DFB, VU-29 and 
CPPHA (O’Brien, et al., 2003; O’Brien et al., 2004; Kinney et al., 2005). The recent 
finding that DFB and VU-29 act through binding to an overlapping site of MPEP 
(Mühlemann et al., 2006; Chen et al., 2007) suggests that the MPEP site is a common site 
shared by multiple allosteric modulators. Similarly, multiple allosteric ligands at mGluR1 
appear to interact with a common site that is homologous with the MPEP site on mGluR5.  
Thus, all known mGluR1 NAMs that have been examined interact with the allosteric site 
labeled by R214127 (Pagano et al., 2000; Litschig et al., 1999). Furthermore, some 
previously characterized mGluR1 PAMs (represented by Ro 67-7476 and VU-71) have 
been postulated to share a homologous binding pocket with MPEP in mGluR5 based on 
critical amino acids implicated in a detailed mutagenesis study (Pagano et al., 2000; 
Knoflach et al., 2001; Hemstapat et al., 2006). However, competition binding assays 
revealed that two other PAMs Ro 67-7476 and VU-71 do not displace the binding of 
radio labeled R214127 (Hemstapat et al., 2006). Thus, we are only at the beginnings of 
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understanding the diversity of allosteric modulatory site on individual mGluR and other 
GPCR subtypes. 
While the current studies suggest that CPPHA does not act by direct interactions 
with the MPEP site, our studies also provide an important hint that the ligands at the 
MPEP site can regulate effects of ligands at the CPPHA site indirectly.  This is based on 
the finding that the neutral MPEP site ligand, 5MPEP, non-competitively inhibits 
CPPHA action.  This is consistent with our previous observation of CPPHA potentiation 
is blocked by another neutral allosteric modulator, DCB (3,3'-dichlorobenzaldazine) 
(Chen et al., 2004).   On the surface, this may imply that ligands at the MPEP site and the 
CPPHA site can allosterically regulate one another. However, if CPPHA could 
allosterically regulate MPEP ligand affinity and vice versa, radioligand binding studies 
should reveal a non-competitive effect of CPPHA on MPEP site binding.  
The finding that mGluR5 PAMS can be identified that act on distinct allosteric 
sites raises the interesting question of whether PAMs that act at these sites will have 
identical effects on mGluR5 function.  In the simplest view, these compounds would 
induce similar increases in activity of mGluR5 regardless of the signaling pathway or cell 
population involved.   However, a growing body of evidence suggests that different 
traditional orthosteric agonists can differentially activate different signaling pathways of 
a single GPCR, a phenomenon referred to as agonist receptor trafficking (Brink et al., 
2000; Gazi et al., 2003; Berg et al., 1998).  Based on this, it is possible that allosteric 
potentiators of mGluRs could differentially regulate coupling of these receptors to 
different signaling pathways.  Further, it is conceivable that PAMs that act at different 
sites could differentially regulate coupling of mGluR5 to different pathways.  mGluR5 
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can couple to multiple signaling pathways and physiological responses.  For instance, we 
reported that mGluR5 in cortical astrocytes activates PI hydrolysis and phosphorylation 
of extracellular signal regulated kinase (ERK2) by completely independent mechanisms 
(Peavy et al., 2001; 2002).  Furthermore, we and a number of other investigators have 
found that activation of mGluR5 can have a wide variety of effects on different neuronal 
populations, including cell depolarization, modulation of different potassium currents, 
potentiation of NMDA receptor currents, and a variety of other responses (see Valenti et 
al., 2002).  It is likely that these responses are mediated by different signaling 
mechanisms and could be differentially regulated.  Interestingly, we recently reported 
that that the MPEP site PAM, DFB, and and CPPHA have subtly different effects on 
mGluR5-mediated responses in astrocytes (Zhang et al., 2005).  Both PAMs potentiate 
mGluR5-mediated increases in intracellular calcium with similar profiles.  This is 
consistent with the similarities of effects of CPPHA and CDPPB on calcium mobilization 
shown in the present manuscript.  Interestingly, DFB and CDPPB have different effects 
on coupling of mGluR5 to ERK1/2 phosphorylation in these same cells (Zhang et al., 
2005).   DFB induces a leftward shift of the agonist concentration response curve for 
ERK1/2 phosphorylation similar to that seen with calcium mobilization.  However, 
CPPHA had a small agonist effect when added alone and potentiated the effect of low 
concentrations of agonist but inhibited the effect of high concentrations of agonist on the 
ERK1/2 phosphorylation response.  When considered in the light of the present findings, 
this raises the possibility that ligands at these two allosteric sites may differentially 
regulated coupling of mGluR5 to these two signaling pathways.  This is also interesting 
in light or previous studies showing that mGluR5 PAMs that act at the MPEP site (ie. 
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CDPPB) have behavioral effects in animal models that can predict antipsychotic-like 
efficacy.  It is not known whether compounds that act at the CPPHA site will have this 
effect.  In future studies, it will be important to systematically compare effects of 
mGluR5 PAMs that act at these different allosteric sites in native systems and in vivo. 
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CHAPTER IV 
 
MGLUR5 PAMS FACILITATES LTP INDUCTION IN THE RAT 
HIPPOCAMPAL CA1 REGION 
 
Introduction 
Metabotropic glutamate receptors (mGluRs) are G-protein-coupled receptors 
(GPCRs) that play important roles in modulating neuronal excitability and synaptic 
transmission at glutamatergic synapses (Conn and Pin, 1997; Schoepp et al., 1999; 
Coutinho and Knopfel, 2002).  Group I mGluRs (mGluR1 and mGluR5) represent one of 
three major subgroups of these receptors and are localized postsynaptically in multiple 
brain regions. Recent studies provide compelling evidence that selective ligands for 
group I mGluRs have potential as therapeutic agents for a range of neurological and 
psychiatric disorders, including disorders involving impaired cognitive function (Kinney 
et al., 2005; Campbell et al., 2004; Moghaddam, 2004; Marino et al 2002; Anwyl 1999).   
A prominent role of group I mGluRs, and especially the mGluR5 subtype, is 
regulation of activity of the NMDA subtype of ionotropic glutamate receptor (see Marino 
and Conn, 2002).  A large number of studies suggest that mGluR5 and NMDA receptors 
are closely associated signaling partners and that mGluR5 plays a critical role in 
maintaining normal NMDA receptor function.  Based on this, it has been postulated that 
increased activity of mGluR5 could enhance NMDA receptor-dependent forms of 
synaptic plasticity and cognitive function.  Consistent with this, mGluR5 knockout mice 
display impairments in NMDA receptor-mediated hippocampal long-term potentiation 
(LTP) and NMDA-dependent memory tasks, such as the Morris water maze and 
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contextual information in the fear-conditioning test (Lu et al., 1997). Also, mGluR5 
selective antagonist MPEP blocks theta burst stimulation (TBS)-induced LTP in area 
CA1 in hippocampal slices (Francesconi et al., 2004; Shalin et al., 2006) and in vivo 
(Manahan-Vaughan and Braunewell, 2005).  Finally, the group 1 mGluR agonist DHPG 
primes LTP induction at relatively low concentrations (Cohen et al., 1998; Raymond et 
al., 2000).   However, multiple studies suggest that activation of mGluR5 may also play a 
critical role in induction of an NMDA receptor-independent form of long-term depression 
(LTD).  DHPG induces LTD in hippocampal area CA1 (Gasparini et al. 1999; Huber et 
al., 2001) and this response is absent in mGluR5 null mice and slices incubated with the 
mGluR5 selective antagonist MPEP (Faas et al. 2002; Gasparini et al. 1999; Hou and 
Klann 2004; Huang and Hsu 2006; Huang et al. 2004 and Huber et al., 2001).   These 
actions of mGluR5 activation on both LTP and LTD could have opposing effects on 
transmission in area CA1 and the precise roles of synaptically activated mGluR5 in 
regulating hippocampal synaptic plasticity are not entirely clear. 
A critical aspect of the majority of studies of mGluR5 involvement in LTD, is that 
these studies rely on exogenous application of group I mGluR agonists and may not 
reflect a response to activation of mGluR5 by synaptically released glutamate.  We have 
now developed novel compounds that act as potent and highly selective positive allosteric 
modulators (PAMs) of mGluR5 (O’Brien, et al., 2003; 2004; Lindsley et al., 2004; 
Kinney et al., 2005; de Paulis et al., 2006; Chen et al, 2007).  These compounds do not 
activate mGluR5 alone but selectively potentiate the receptor’s response to glutamate.  
This provides an exciting new tool that allows selective potentiation mGluR5 activation 
by glutamate with afferent stimulation. We have now determined the effect of selective 
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potentiation of the mGluR5 response to afferent stimulation on rat hippocampal CA1 
plasticity.  Interestingly, our studies suggest that mGluR5 potentiation enhances induction 
of hippocampal LTP in response to stimuli that are at the threshold for inducing LTP 
under normal conditions.    
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Material and Methods 
 
Hippocampal slices PI hydrolysis assay. 
Agonist-induced PI hydrolysis was measured in rat hippocampal slices using a 
modification of method outlined by Berridge et al. (1982) as previously described (Conn 
and Sanders-Bush, 1986). Briefly, cross-chopped (350 µM X 350 µM) slices of male (6-9 
weeks) Sprague-Dawley rat hippocampus were incubated with 95% O2 5% CO2 bubbled 
Krebs buffer (108 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.5 mM 
CaCl2, 25 mM NaHCO3 and 10 mM Glucose). The tissue was allowed to recover for 30 
minutes with shaking at 37ºC. Following tissue recovery, the tissue was combined, 
washed with warm Krebs buffer, and 25 µL of gravity packed slices were incubated with 
175 µL Krebs containing 0.5 µCi [3H]myo-inositol for 45 minutes. VU-29 or vehicle 
controls were added and incubated for 15 minutes, followed by the addition of 10 mM 
LiCl and incubation for an additional 15 minutes.  Finally, DHPG was added followed by 
an additional 45 minute incubation. The reaction was terminated by the addition of 900 
µL of chloroform:methanol (1:2). The aqueous and organic phases were separated by 
addition of 300 µL chloroform and 300 µL water, vortexing, and allowing the phases to 
separate by gravity. The aqueous phase was added to anion exchange columns (AG 1-X8 
Resin, 100-200 mesh, formate form, BIO-RAD) and [3H]inositol phosphates were eluted 
and measured by liquid scintillation counting.  
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Electrophysiology. 
Brains were removed from young adult (6-9 weeks) male Sprague-Dawley rats 
and 400 μM transverse slices were prepared using a vibratome (Leica Microsystems, 
Nussloch, Germany. Drugs were diluted to the appropriate concentrations in either 
DMSO (< 0.1%) or aCSF (125 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 1.25 mM 
NaH2PO4, 2 mM CaCl2, 25 mM glucose, and 25 mM NaHCO3, equilibrated with 95% 
O2/5% CO2) and applied to the slice at a rate of 2 mL/min. Extracellular field potentials 
were recorded from slices that recovered in an interface chamber perfused with 
oxygenated aCSF (2 mL/min) for at least 1.5 hrs at 31°C. Bipolar stimulating electrodes 
were placed in the stratum radiatum near the CA3-CA1 border in order to stimulate the 
Schaffer collaterals.  Recording electrodes were pulled with a Flaming/Brown 
micropipette puller (Sutter Instruments) to a resistance of 3-5MΩ, filled with aCSF and 
placed in the stratum radiatum of area CA1. Field potential recordings were acquired 
using an A-M systems 1800 amplifier and pClamp 9.0 software. The 40% maximal 
stimulus intensity was determined prior to each experiment. Baseline stimulation was 
presented at 0.05 Hz.  LTP was induced by either one train or four trains of theta burst 
stimulation (TBS)(threshold TBS: nine bursts of four pulses at 100 Hz; 230 ms interburst 
interval; 10 HZ TBS: nine bursts of four pulses at 100 Hz; 100 ms interburst interval).  
Cell Based Calcium Fluorescence Measurement.  
Secondary rat cortical astrocytes were prepared as described previously (Chen et 
al., 2007; Peavy et al., 2001; Zhang et al., 2005).  Rat mGluR1d was transfected into 
HEK293A cells using Lipofectamine as described previously (Chen et al., 2007).  Rat 
mGluR2 and human mGluR4 were co-expressed with Gqi5, which enables coupling to the 
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calcium mobilization as reported by Galici et al. (2006). Cells were loaded with calcium-
sensitive dye according to the manufacturer's instructions (Calcium 3 kit; Molecular 
Devices, Sunnyvale, CA) after incubation in glutamate/glutamine-free medium (DMEM 
and 10% dialyzed fetal bovine serum) for 5 h. Compound A (1 ml) from Calcium 3 kit 
was dissolved in 20 ml of 1x Hanks' balanced salt solution (HBSS; Invitrogen) containing 
2.5 mM probenecid (Sigma), adjusted to pH 7.4. Cells were loaded for 50 min at 37°C 
with 5% carbon dioxide. Dye was then carefully removed, and cells were washed with 
HBSS containing probenecid. Cells were maintained in the same buffer at room 
temperature for the following assay. For calcium fluorescence measurement of rat cortical 
astrocytes, allosteric modulators were added 5 min before the addition of agonist 
manually. Agonist was added at a speed of 52 µl/s, and calcium flux was measured using 
Flexstation II (Molecular Devices) at 25°C. All of the peaks of the calcium response were 
normalized to the maximum response to a saturated dose of glutamate (10 µM). The 
submaximal concentration (EC20 value) of glutamate was determined for every separate 
experiment, allowing for a response varying from 10 to 30% of the maximum peak. 
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Results 
 
VU-29 potentiates DHPG-induced phophoinositide hydrolysis in the rat 
hippocampal slices.    
 
In previous studies, cell culture and recombinantly expressed mGluRs were used 
to demonstrate the mGluR5 PAM activity of VU-29 (Chen et al., 2007).  Prior to using 
this compound for studies of the role of mGluR5 in hippocampal LTP, we verified that 
this compound potentiates mGluR5-mediated responses in hippocampal slices by 
determining the effect of this compound on mGluR5-mediated increases in PI hydrolysis.  
Consistent with previous studies (Sacaan et al., 1998; Johnson et al., 1999; Gasparini et 
al., 1999), DHPG induced a concentration-dependent increase in PI hydrolysis in rat 
hippocampal slices (Figure 4-1A).  Consistent with its effect on mGluR5-mediated 
calcium mobilization in cell lines, VU-29 (500 nM) had no effect on the baseline PI 
hydrolysis but induced a leftward shift in the DHPG concentration response curve (CRC) 
and enhanced the maximum response (Figure 4-1A; Student’s t-test, p<0.05) (Figure 4-
1A).  We then determined the effect of VU-29 on the response to a single concentration 
of DHPG that induced and approximate EC20 PI hydrolysis response (3 µM).   At this 
concentration, DHPG (3 µM) induced a small but significant increase in PI hydrolysis 
compared with vehicle control (Figure 4-1B; Student’s t-test, P<0.05), which was 
significantly potentiated by VU-29 (5 µM) (Figure 4-1B; Student’s t-test, P<0.05) but not 
by the neutral mGluR5 ligand, 5MPEP (100 µM) (Figure 4-1B; Student’s t-test).  Also 
consistent with previous studies in cell culture systems, the potentiation of DHPG-
induced PI hydrolysis in hippocampal slices by VU-29 was completely blocked by 
5MPEP (Figure 4-1B; Student’s test, P<0.05).   
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Figure 4-1: VU-29 potentiates DHPG-induced PI hydrolysis in rat hippocampal slices. A. 
500nM VU-29 significantly potentiated the dose response curve of DHPG-induced PI 
hydrolysis in the rat hippocampal slices. In the presence of VU-29 the EC50 of DHPG 
was 4.3 ± 1.1 µM, significantly lower than vehicle control of 6.7 ± 1.8 µM.  Additionally, 
the maximum response was also enhanced 1.38 ± 0.13 folds.  B. 3 µM DHPG increased 
baseline PI hydrolysis, which was significantly enhanced by pre-incubation of 5 µM VU-
29 but not altered by 100 µM 5MPEP using rat hippocampal slices. 5MPEP blocked the 
potentiation caused by VU-29. (n=5, done in triplicate).  Error bars represent S.E.M. 
(This figure was contributed by Dr. Douglas J. Sheffler)
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VU-29 potentiates threshold TBS-induced LTP in rat hippocampal CA1 region.   
To determine the effect of VU-29 on TBS-induced LTP, field EPSPs (fEPSPs) 
were recorded from SC-CA1 synapses.  Application of 500 nM VU-29 had no effect on 
the baseline synaptic responses as measured by initial fEPSP slope (Figure 4-2A).  In the 
absence of VU-29, a single train of threshold TBS induced a slight potentiation of EPSPs 
(115 + 6% of control at 45 min post TBS).  Interestingly, this same TBS protocol induced 
robust LTP in slices incubated with VU-29 (500 nM) for 20 min prior to application of 
TBS (152 + 8% of control at 45 min post TBS) (Figure 4-2B; Student’s T-test, P<0.05).  
5MPEP (100 µM) completely blocked TBS-induced LTP in the presence of VU-29 (92 + 
14% of control at 45 min post TBS) (Figure 4-3A), suggesting that the action of VU-29 is 
due to actions on mGluR5.  In contrast, 5MPEP (100 µM) had no effect on induction of 
LTP by 10 HZ TBS protocol which is sufficient to induce robust LTP in the absence of 
VU-29 (192 + 19% of control at 45 min post TBS in the absence of 5MPEP; 185 + 13% 
of control 45 min post TBS in the presence of 5MPEP) (Figure 4-3B).  This suggests that 
the effect of 5-MPEP is specific to the VU-29 potentiation and excluded the possibility 
that 5MPEP blocked LTP induction through blockade of signaling components required 
for LTP induction other than mGluR5.  VU-29 did not alter pared pulse facilitation, fiber 
valley amplitude and input-output curve compared with vehicle controls (data not shown). 
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Figure 4-2: The mGluR5 PAM VU-29 facilitates the induction of LTP in area CA1 of the 
hippocampus. A. A 30 min incubation of 500 nM VU-29 did not alter the baseline fEPSP 
recorded from rat hippocampal CA1 region (n=8). B. In control slices, threshold TBS 
induced marginal potentiation of fEPSP. In the presence of VU-29 the same stimulation 
(20 min pre-incubation) yielded a significant potentiation (n=12; Student’s T-test, 
P<0.05). Error bars represent S.E.M. (This figure was contributed by Dr. Jessica L. 
Banko partially)
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Figure 4-3. The VU-29-LTP is blocked by 5MPEP. A. Pre-incubation of 100 µM 5MPEP 
completely inhibited VU-29 facilitated TBS induced LTP back to vehicle control (n=8; 
Student’s t-test). B. 10 HZ TBS-induced LTP was not altered by the pre-incubation of 
100 µM 5MPEP (n=8; Student’s t-test).  Error bars represent S.E.M. (This figure was 
contributed by Dr. Jessica L. Banko partially)
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VU-29 does not potentiate LTP induced by suprathreshold TBS or alter established 
saturated LTP.   
 
The finding that selective potentiation mGluR5 responses enhances threshold 
TBS LTP suggests that mGluR5 can play an important role in regulating synaptic 
plasticity in response to stimulus trains that are just below the threshold needed to induce 
a robust LTP response.  It is possible that this represents a potentiation of the normal 
processes underlying TBS LTP.  Alternatively, mGluR5 activation could induce another 
form of LTP that is superimposed on the normal potentiation induced by threshold TBS.  
If the latter is the case, VU-29 may be expected to potentiate the LTP response to a 
suprathreshold TBS protocol.  Furthermore, it is possible that VU-29 could further 
potentiate saturated LTP that has been established.  Finally, if potentiation of mGluR5 
induces competing processes leading to both induction of LTP and LTD, it is possible 
that VU-29 could actually decrease the magnitude of LTP induced by a suprathreshold 
stimulation or facilicate depotentiation of a saturated LTP response. To address this, we 
determined the effect of VU-29 on the LTP response to suprathreshold TBS stimulation.  
Interestingly, VU-29 had no effect on the LTP response when a stimulus protocol was 
used (4 trains of 10 HZ TBS) that induces robust LTP in the absence of VU-29 (Figure 4-
4A) (178 + 9%%potentiation at 30 min post TBS in the absence of VU-29; 176 + 9%% 
potentiation in the presence of VU-29).    We then applied VU-29 to slices in which a 
maximal LTP response had been established to determine whether VU-29 would alter the 
response to TBS stimulation in under conditions of saturated LTP.  As with the response 
to a single suprathreshold TBS protocol, VU-29 had no effect on the response to 
suprathreshold LTP in slices in which LTP had been saturated (Figure 4-4B).  These 
indicated VU-29 facilitated LTP utilized the same signaling machineries as normal   
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Induction of LTP in the presence of VU-29 is dependent on activation of NMDA 
receptors and src family kinases.     
 
Previous studies suggest that induction of LTP at the SC-CA1 synapse by 
suprathreshold TBS is dependent on activation of both NMDA receptors and src family 
kinases (Collingridge et al., 1987; Lu et al., 1998; Salter et al., 2004).  Also, previous 
studies suggest that activation of mGluR5 potentiates NMDA receptor currents and that 
mGluR5-induced activation of src family kinases is important for this response (Doherty 
et al., 1997, 2000; Jia et al., 1998; Awad et al., 2000; Mannaioni et al., 2001; Benquet et 
al., 2002; Gerber et al., 2007). Thus, it is likely that potentiation of synaptically activated 
mGluR5 by VU-29 enhances induction of normal NMDA receptor-dependent LTP.   
However, it is also possible that VU-29 leads to induction of a distinct form of LTP that 
is independent of NMDA receptor and src family kinase activation.  To control for this 
possibility to verify that TBS LTP is dependent on activation of the same signaling 
pathways in VU-29 treated slices, we determined the effects of the NMDA receptor 
antagonist, D-AP5 and the src family kinase inhihbitor PP1 on TBS-induced LTP in the 
presence of VU-29 (Figure 4-5).  Both D-AP5 (50 µM) and PP1 (20 µM) completely 
blocked induction of LTP by the combination of VU-29 and threshold TBS (Figure 4-5). 
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Figure 4-4: VU-29 facilitated LTP shares similar mechanisms as TBS-induced LTP in 
area CA1 of the hippocampus. A. Saturated TBS-induced LTP occluded 500nM VU-29 
facilitated LTP. LTP was induced by 4 trains of 10 HZ TBS. After 30 minutes, the slices 
were incubated with 500 nM VU-29, followed by another 4 trains of 10 HZ TBS, which 
did not overcome the potentiation induced by the first 4 trains of TBS (n=8; Student’s t-
test).  B. 500 nM VU-29 did not alter saturated TBS-induced LTP. In control slices, a 4X 
100 HZ TBS-induced saturated potentiation. The same stimulation in the presence of 
VU-29 yielded a potentiation with no significant difference compared with control (n=5; 
Student’s t-test).  Error bars represent S.E.M. 
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Figure 4-5: NMDA Receptor antagonist and Src family kinase inhibitor block VU-29 
facilitated LTP of fEPSP in rat hippocampal CA1 region.  50 µM NMDA receptor 
antagonist, D-AP5 (A), or 20 µM Src family kinase inhibitor, PP1 (B), completely 
blocked TBS-induced LTP in the presence or absence of VU-29 (n=8; Student’s T-test).  
Error bars represent S.E.M. (This figure was contributed by Dr. Jessica L. Banko 
partially)
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 A structurally distinct mGluR5 PAM has similar effects to VU-29 on threshold TBS-
induced LTP.     
 
Epping-Jordan et al., (2005) recently presented a preliminary report of a novel 
mGluR5-selective PAM, termed Addex-47273 that is structurally unrelated to VU-29.  
Unfortunately, ADX-47273 was only presented in abstract form.    However, if mGluR5 
PAM activity of this compound could be verified, this would provide an excellent 
additional tool to provide further evidence that selective potentiation of mGluR5 
potentiates LTP and that the actions of VU-29 are mediated by potentiation of mGluR5.  
Thus, we established a protocol for synthesis of ADX-47273 and characterized this 
compound to verify that it is a selective mGluR5 PAM.  In previous studies, we have 
rigorously characterized DHPG-induced calcium mobilization in secondary cultured rat 
cortical astrocytes and found that this response is exclusively mediated by mGluR5 
(Peavy et al., 2002) and that mGluR5 PAMS induce a robust potentiation of this response 
(Zhang et al., 2005; Rodriguez et al., 2005; Hemstapat et al 2006; Chen et al., 2007).  
ADX-47273 induced a robust potentiation of glutamate-induced calcium mobilization in 
cortical astrocytes in a manner similar to that previously reported for VU-29 and other 
mGluR5 PAMS (Figure 4-6). Thus, ADX-47273 induced a concentration-dependent 
potentiation of the response to an EC20 – EC30 concentration of glutamate (300 nM) 
with an EC50 value of 108 ± 41 nM (Figure 4-6).  Furthermore, ADX-47273 (10 µM) did 
not affect the glutamate concentration response curves of mGluR1, mGluR2 and mGluR4 
(Figure 4-7; Student’s T-test), suggesting that this compound is selective as a PAM for 
mGluR5 relative to these other mGluR subtypes.  Consistent with the effects of VU-29, 
(Figure 4-2B), ADX-47273 (10 µM) induced a significant increase in threshold TBS-
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induced LTP of fEPSPs in the rat hippocampal CA1 region (Figure 4-8) (134 + 7% 
potentiation at 30 min post TBS in vehicle; 173 + 9% potentiation at 45 min post TBS in 
ADX-47373).   
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Figure 4-6: ADX-47273 is a novel mGluR5 selective PAM from a different structural 
family. Using secondary cultured rat cortical astrocytes, intracellular calcium 
mobilization responses were measured in response to an EC20-30 concentration of 
glutamate in the absence or presence of different concentrations of Addex-47273. The 
EC20-30 concentration for glutamate was determined each day which was about 300 nM. 
Data were normalized to the maximum response of each reaction determined by 10 µM 
glutamate. The potency of ADX-47273 was determined to be 108 ± 41 nM.  A shows the 
CRC of ADX-47273. B shows the Calcium mobilization traces of a representative 
experiment. Concentration-response curves were generated from three independent 
experiments each performed in duplicate. Error bars represent S.E.M. 
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Figure 4-7: ADX-47273 does not potentiate mGluR1-, -2-, or -4-mediated responses. A 
concentration of Addex-47273 that maximally potentiated mGluR5 responses (10 µM) 
neither potentiated nor antagonized mGluR1- (A), mGluR2- (B), and mGluR4-mediated 
(C) responses in transiently transfected HEK 293A cells as measured using the calcium 
mobilization assay. Concentration-response curves were generated from three to four 
independent experiments performed in duplicate (Student’s T-test). Error bars represent 
S.E.M. 
 
 
 
 121
  
-10 0 10 20 30 40 50
0
50
100
150
200
250 Addex-47273 10μM
Vehicle
TBS
Time (Min)
%
fE
PS
P 
Sl
op
e
Figure 4-8: ADX-47273 facilitates threshold TBS-induced LTP in rat hippocampal CA1 
region. In control slices, TBS delivered in the presence of vehicle resulted in a marginal 
potentiation of the fEPSP. The same threshold TBS delivered in the presence of 10 µM 
ADX-47273, induced a significantly larger potentiation of the fEPSP up to 45 minutes 
after stimulation (n=8; Student’s T-test, P<0.05).  Error bars represent S.E.M. 
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Discussion 
The present studies provide compelling evidence that selective mGluR5 PAMs 
enhance induction of LTP by a TBS protocol that is not sufficient to induce robust LTP in 
the absence of mGluR5 potentiation.    This effect was seen with two structurally distinct 
mGluR5 PAMs and blocked by a compound belonging to a third structural class that has 
been developed to selectively block the actions of mGluR5 allosteric modulators on 
mGluR5.  This adds to a large literature that has implicated group I mGluRs as playing a 
role in synaptic plasticity in hippocampal area CA1 and is consistent with previous 
findings that mGluR5 knockout mice display impaired LTP in area CA1 (Lu et al., 1997) 
and that mGluR5 antagonists block TBS-induced LTP in this region (Francesconi et al., 
2004; Shalin et al., 2006; Manahan-Vaughan and Braunewell, 2005). Furthermore, bath 
application of the group 1 mGluR selective agonist DHPG primes hippocampal LTP 
induction at relatively low concentrations (Cohen et al., 1998; Raymond et al., 2000). 
However, despite these previous studies, the impact of mGluR5-selective PAMs 
on afferent stimulation-induced LTP was difficult to predict prior to the present studies.  
For instance, other studies have reported that mGluR5 antagonists do not block LTP 
induced by high frequency titanic stimulation (Bortolotto et al., 2005; Fitzjohn et al., 
1998). Additionally, higher concentrations of DHPG induce LTD in CA1 region 
(Gasparini et al. 1999; Huber et al., 2001), which is absent in mGluR5 null mice and 
could be blocked by MPEP from some studies (Faas et al. 2002; Gasparini et al. 1999; 
Hou and Klann 2004; Huang and Hsu 2006; Huang et al. 2004 and Huber et al., 2001).    
Based on this, it was difficult to predict whether selective potentiation of activation of 
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mGluR5 by afferent stimulation would enhance or reduce LTP, or would lead to 
induction of LTD by administration of stimuli that are subthreshold for induction of LTP.   
While the present studies provide strong evidence in support of a role for mGluR5 
in hippocampal TBS-induced LTP, they do not rule out the possibility that mGluR5 can 
also participate in induction of afferent stimulation-induced LTD under some conditions 
or stimulus protocols.  It is conceivable that activation of mGluR5 by different stimulus 
protocols or in different physiological settings determines whether this receptor is more 
likely to lead to long term potentiation or depression or synaptic transmission.  However, 
we saw not evidence that the mGluR5 PAM could promote long term depression of 
synaptic transmission under any of the stimulus protocols used here.  This includes 
modest TBS that does not induce robust LTP, suprathreshold TBS that induces robust 
LTP, and application of intense TBS in slices in which LTP was already saturated.    
While a role for mGluR5 in induction of LTD by afferent stimulation in the 
hippocampus remains a viable possibility, it is important to note that the large majority of 
studies implicating mGluR5 in induction of hippocampal LTD have relied on measuring 
responses to exogenous application of DHPG to hippocampal slices rather than activation 
of mGluR5 by afferent stimulation.  Early studies suggested that a nonselective group I 
mGluR antagonist can block one form of low frequency stimulation-induced LTD at the 
SC-CA1 synapse (Oliet et al., 1997; Nicoll et al., 1998).  However, the mGluR5-selective 
antagonist MPEP does not reduce afferent stimulation-induced LTD (Volk et al., 2006), 
suggesting that the effect of the more non selective antagonist are not likely mediated by 
blockade of mGluR5.  Furthermore, DHPG activates both mGluR1 and mGluR5 and 
recent studies suggest that DHPG-induced LTD can only be inhibited by combined 
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blockade of both mGluR1 and mGluR5, suggesting that both receptors are important for 
mediating the response to exogenous agonist application (Volk et al., 2006).  Thus, 
further studies are needed to develop a more complete understanding of the relative roles 
of mGluR1 and mGluR5 in both agonist- and afferent stimulation-induced LTD.   
The mechanism by which activation of mGluR5 enhances hippocampal LTP is 
not known.  Activation of this receptor has multiple actions that could contribute to this 
response.  The most obvious possibility is that this is mediated by the known ability of 
mGluR5 to potentiate currents through the NMDA receptor (Doherty et al., 1997, 2000; 
Jia et al., 1998; Awad et al., 2000; Mannaioni et al., 2001).   TBS-induced LTP at the SC-
CA1 synapse is known to be dependent on NMDA receptor activation and potentiation of 
NMDA receptor function by mGluR5 provides an obvious mechanism that could 
contribute to this response.  Consistent with this, TBS LTP in the presence of VU-29 
remains NMDA receptor dependent.  Also, the response is blocked by PP1, an inhibitor 
of src family kinases that are known to be critical for mGluR5 potentiation of NMDA 
receptor currents in CA3 pyramidal cells (Benquet et al., 2002).   However, it is also 
possible that other actions of mGluR5 activation participate in regulation of hippocampal 
LTP.  Activation of mGluR5 has a number of effects in area CA1 including blockade of 
AHP-type potassium currents in CA1 pyramidal cells (Mannaioni et al., 2001), 
depression of inhibitory synaptic transmission (Mannaioni et al., 2001), and acute 
potentiation of depolarization-induced glutamate release (Herrero et al., 1998; Rodríguez-
Moreno et al., 1998; Fiacco et al., 2004). Also, mGluR5 activation induces depolarization 
of multiple other neuronal populations (Awad et al., 2000; Valenti et al., 2002).  While 
mGluR1 is the primary group I mGluR subtype responsible for depolarization CA1 
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pyramidal cells recorded in the soma, it is possible or likely that mGluR5 could 
contribute to depolarization in dendrites and this could also contribute to the overall 
actions of mGluR5 activation.  Finally, mGluR5 is also localized in astrocytes in the 
hippocampus where it activates PI hydrolysis and phosphorylation of extracellular signal 
regulated kinase (ERK2) (Peavy et al., 2001; 2002). Recently it has been shown that 
astrocytes could play a key role in regulating synaptic plasticity by releasing the NMDA 
receptor co-agonist D-Serine (Yang et al., 2003). Activation of mGluRs in astrocytes 
induces D-serine release (Kim et al., 2005, Mothet et al., 2005 and Schell et al., 1995), 
raising the possibility that this could also contribute to the effects of mGluR5 PAMs. In 
total, these combined effects of mGluR5 activation in the hippocampal formation would 
dramatically increase excitatory drive, neuronal excitability, and NMDA receptor 
activation in CA1 pyramidal cells, which could prime the cells for efficient induction of 
LTP.   
In addition to implications for the mechanisms underlying hippocampal LTP and 
a possible role of mGluR5 in this process, these studies have important implications 
related to the possible development of mGluR5 PAMs as therapeutic agents.  Discovery 
of selective PAMS for mGluR5 and other G-protein-coupled receptors has generated a 
great deal of interest in the possibility of developing this class of small molecules as a 
novel approach for treatment of CNS disorders (Christopoulos et al., 2002; May et al., 
2004; Brauner-Osborne et al., 2007).  For mGluR5, a large number of anatomy, 
electrophysiology, and behavioral studies with mGluR5 antagonists led to the hypothesis 
that activation of mGluR5 could have potential utility as a novel approach to treatment of 
schizophrenia (Marino and Conn, 2002).  Unfortunately, it has been difficult to develop 
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agonists that selectively activate mGluR5 and have properties that are desirable in drug-
like molecules.  Furthermore, direct-acting receptor agonists can have problems 
associated with excessive receptor activation and strong desensitization that lead to 
adverse effects and tolerance with chronic administration.   Discovery of highly selective 
mGluR5 PAMs such as VU-29 provided a major breakthrough and a novel approach to 
increasing activity of this receptor.  Consistent with the hypothesis that these compounds 
have potential as novel antipsychotic agents, we found that a close analog of VU-29, 
termed CDPPB, has antipsychotic-like effects in two rodent models that are used to  
predict efficacy of novel agents at reversing the positive symptoms (ie psychosis) seen in 
schizophrenic patients (Kinney et al., 2005). Furthermore, Moghaddam et al. (2004) 
reported that CDPPB has effects on cell firing in the cortex that are opposite to those of 
psychomimetic agents.  These data are consistent with the possibility that mGluR5 PAMs 
could prove to have antipsychotic efficacy.  The present studies raise the possibility that, 
in addition to efficacy in treatment of positive symptoms of schizophrenia, mGluR5 
PAMs could also have effects that may enhance impaired cognitive function.  This could 
provide a major benefit relative to existing antipsychotic agents and raises the possibility 
that these compounds should also be evaluated for efficacy in models of other diseases 
that involve impaired cognitive function.  Consistent with this, Balschun et al (2006) 
recently reported that icv injection of the mGluR5 PAM DFB, induces a marked 
improvement in spatial alternation retention when it was tested 24 hr after training.  
These data are consistent with the present findings and suggest that mGluR5 PAMs can 
enhance at least one form of hippocampal-dependent memory.  In addition, exciting 
advances with allosteric potentiators of other mGluR subtypes suggest that these 
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compounds often have robust behavioral effects that are similar to those of direct-acting 
orthosteric agonists.  For instance, we recently developed PHCCC as an allosteric 
potentiator of mGluR4 and found that this compound has antiparkinsonian effects in 
rodent models that are similar to those of the traditional agonist L-AP4 (Valenti et al., 
2003; Marino et al., 2003).  Furthermore, we (Galici et al., 2006) and others (Johnson et 
al., 2003; 2005) found that novel allosteric potentiators of mGluR2 have robust 
behavioral effects similar in rodent models that predict anxiolytic and antipsychotic 
activity.  In future studies, it will be important to expand our understanding of the 
behavioral effects of mGluR5 PAMs and further evaluate the potential utility of these 
compounds in measures of cognitive function. 
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CHAPTER V  
 
SUMMARY 
 
Exciting progress has been made in the discovery of selective positive allosteric 
modulators of mGluR5. These compounds may provide a novel approach that could be 
useful in the treatment of certain central nervous system disorders, such as schizophrenia. 
However, because of their relatively low potencies, previously described mGluR5 PAMs 
are not useful for functional studies in native preparations. In addition, their 
pharmacological properties are not clear, including their sites of action and interactions 
with other mGluR5 allosteric modulators. It has been suggested that two allosteric 
potentiators, DFB and CDPPB, act by binding to the same allosteric site as the negative 
allosteric modulators of mGluR5 such as MPEP, because both of them reduce binding to 
the MPEP site. However, CPPHA, another mGluR5 PAM from a distinct structural 
family, does not bind to this site.  Moreover, DFB reduces MPEP site binding only 
partially and CDPPB has a much lower affinity to MPEP site than its potency as mGluR5 
PAM.  All of these bring the site of action in mGluR5 into question.  
We have synthesized a series of CDPPB analogs and report that these compounds 
bind to the MPEP site with affinities that are closely related to their potencies as mGluR5 
potentiators. Furthermore, allosteric potentiation is antagonized by  a neutral ligand at the 
MPEP site and reduced by a mutation of mGluR5 that eliminates MPEP binding. 
Together, these data suggest that interaction with the MPEP site is important for allosteric 
potentiation of mGluR5 by CDPPB and related compounds. In addition, whole-cell 
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patch-clamp studies in midbrain slices reveal that a highly potent analog of CDPPB, VU-
29, selectively potentiates mGluR5 but not mGluR1-mediated responses in midbrain 
neurons, whereas a previously identified allosteric potentiator of mGluR1 has the 
opposite effect.    
The finding that the binding to the MPEP site is important for the action of VU-29 
suggests that CPPHA might act at a distinct site, especially when combined with the fact 
that it does not to bind to the MPEP site.  As the second part of my graduate study, we 
have reported that CPPHA potentiates mGluR5 responses by a mechanism that is distinct 
from that of VU-29.  VU-29- and CPPHA-induced potentiation of mGluR5 responses are 
blocked by a neutral ligand at the MPEP alloteric site termed 5MPEP.  However, 
increasing concentrations of 5MPEP induce parallel rightward shifts in the VU-29 
concentration response curve (CRC) whereas 5MPEP inhibits CPPHA potentiation in a 
non-competitive manner.  Consistent with this, a mutation (A809V/mGluR5) that reduces 
binding of ligands to the MPEP site eliminates the effect of VU-29 but has no effect on 
the response to CPPHA.  Conversely, a mutation that eliminates the effect of CPPHA 
does not alter the response to VU-29.  CPPHA is also a PAM at mGluR1. Interestingly, 
the corresponding mutation of F585I/mGluR5 in mGluR1 (F599I/mGluR1) eliminates 
CPPHA’s effect without altering the potentiation of a known PAM of mGluR1 (Ro 67-
7476).  Likewise, another mutation (V757L/mGluR1) abolishes potentiation of Ro 67-
7476 has no effect on CPPHA.  Finally, CPPHA does not displace binding of a 
radioligand for the previously characterized mGluR1 allosteric antagonist.  Together, 
these data suggest that CPPHA acts at a novel allosteric site on both mGluR1 and 5 to 
potentiate responses to activation of these receptors. 
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mGluR5 has been implicated as playing an important role in hippocampal 
synaptic plasticity. However, the precise roles of mGluR5 in different forms of 
hippocampal synaptic plasticity remain unclear.  In the third part of my study, we took 
the advantage of the novel pharmacological tools, mGluR5 selective PAMs, to determine 
the effect of selectively increasing activation of mGluR5 in response to stimulation of 
glutamatergic afferents at the Schaffer collateral – CA1 (SC-CA1) synapse in the 
hippocampus. The selective mGluR5 PAM, VU-29, potentiated DHPG-induced PI 
hydrolysis in rat hippocampal slices and this effect was blocked by 5MPEP, an mGluR5-
selective neutral allosteric site ligand.   Thus, VU-29 and 5MPEP have effects in 
hippocampal slices that are consistent with those observed in recombinant systems. 
Interestingly, VU-29 did not affect basal synaptic transmission at the SC-CA1 synapse 
but significantly enhanced threshold theta burst stimulation (TBS)-induced long-term 
potentiation (LTP).  This LTP induction was completely blocked by 5MPEP and was 
mimicked by ADX-47273, a structurally distinct mGluR5-selective PAM, providing 
further support for a critical role of mGluR5.  In addition, VU-29 potentiated LTP was 
blocked by the NMDA receptor antagonist, D-AP5 or by the src kinase inhibitor, PP1, 
suggesting that it shares a common mechanism with suprathreshold TBS-induced LTP.   
Interestingly, VU-29 had no effect on LTP induced by suprathreshold TBS stimuli or on 
saturated LTP.  These data suggest that selective potentiation of synaptically activated 
mGluR5, facilitates threshold TBS-induced LTP in the rat hippocampal CA1 region, and 
raise the possibility that these agents could be used as potential cognition enhancing 
agents. 
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In summary, we have identified two distinct crucial sites for the action of two 
different families of mGluR5 PAMs respectively and shown their differential 
pharmacological properties. It has been shown that DFB and CPPHA could regulate 
mGluR5-mediated ERK1/2 phosphorylation differentially. Our finding is crucial to 
understand these different actions of mGluR5 PAMs and could orient future development 
of mGluR allosteric modulators. Meanwhile we have reported the first evidence that 
mGluR5 PAMs potentiates threshold TBS-induced LTP in rat hippocampal CA1 region. 
This is helpful to understand the fundamental role of mGluR5 in neuronal plasticity and 
suggest mGluR5 PAMs could have the potential to be cognition enhancing reagents. 
There are however still questions remaining about this phenomenon.  For instance, the 
mechanism of action is still unclear.  Also, the effect of mGluR5 PAMs on LTD has not 
been addressed.  These are all future directions for our lab to pursue. 
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